IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 6,673,838

Inventors: HADFIELD, Anthony F. et al.

Issue Date: January 6, 2007

For: SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE

Assignee: Wyeth

Date: April 25, 2008

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPLICATION FOR EXTENSION OF PATENT
TERM UNDER 35 U.S.C. §156

Commissioner for Patents:

Applicant, Wyeth, a corporation organized and existing under the laws of Delaware, and having a principal place of business at 5 Giralda Farms, Madison, NJ 07490, represents that it is the owner of the entire interest in and to U.S. Patent No. 6,673,838, granted to Anthony Francis Hadfield, Syed M. Shah, Michael W. Winkley, Karen W. Sutherland, James A. Provost, Aeri Park, Rex A. Shiplett, Brenton W. Russell, and Beat T. Weber for "Succinate Salt of O-desmethyl-venlafaxine," as reflected in the various assignment documents recorded by the U.S. Patent and Trademark Office on August 27, 2001 at Reel 012126, Frame 0893, on August 27, 2001 at Reel 012127, Frame 0102, on April 12, 2002 at Reel 012828, Frame 0928, on July 30, 2002 at Reel 013121, Frame 0837, on July 30, 2002 at Reel 013121, Frame 0855, on July 31, 2002 at Reel 013127, Frame 0287, on July 31, 2002 at Reel 013127, Frame 0306, on August 1, 2002 at Reel 013130, Frame 0479, and on August 21, 2002 at Reel 013229, Frame 0864. Attached at **Exhibit A** is a Power of Attorney document appointing the undersigned patent attorney as legal representative of Applicant.

U.S. Patent No. 6,673,838
Transmittal Application for Extension of Patent

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1349.

Respectfully submitted,

HOGAN & HARTSON LLP

Dated: April 25, 2008

By: _____
Celine Jimenez Crowson
Registration No. 40,357

Kevin G. Shaw
Registration No. 43,110

HOGAN & HARTSON LLP
555 Thirteenth Street, N.W.
Washington, D.C. 20004
Telephone: 202-637-5703
Facsimile: 202-637-5910
e-mail: cjcrowson@hhlaw.com
Customer No. 24633

Wyeth Pharmaceuticals is a wholly owned division of Wyeth and has a principal place of business at 5 Giralda Farms, Madison, NJ 07490. Wyeth Pharmaceuticals is the owner of a New Drug Application ("NDA") for PRISTIQ™, NDA number NDA 21-966. Attached at **Exhibit A** is a Power of Attorney document appointing the undersigned patent attorney as legal representative of Applicant and as agent of Wyeth and its division Wyeth Pharmaceuticals for purposes of requesting and/or obtaining any patent term extensions with respect to NDA number 21-966.

Applicant, acting through its duly authorized attorney, hereby submits this application for extension of patent term under 35 U.S.C. §156, based upon the approval by the Food and Drug Administration for commercial marketing or use of PRISTIQ™, since the active ingredient of PRISTIQ™ is desvenlafaxine succinate, which falls within the ambit of the claims of U.S. Patent No. 6,673,838. The information contained in this Application and its Exhibits is provided in accordance with the rules promulgated by the U.S. Patent and Trademark Office at 37 CFR §§1.710-1.785 and presented in the manner set forth at 37 CFR §1.740.

1. A Complete Identification Of The Approved Product As By Appropriate Chemical And Generic Name, Physical Structure Or Characteristics

The approved product, PRISTIQ™, contains desvenlafaxine succinate as its active ingredient. The chemical name of desvenlafaxine (also known as O-desmethyl venlafaxine) is RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula $C_{16}H_{25}NO_2$. Desvenlafaxine succinate is a succinate salt of desvenlafaxine, and has the empirical formula $C_{16}H_{25}NO_2 \cdot C_4H_6O_4$ ($C_{16}H_{25}NO_2 \cdot C_4H_6O_4 \cdot H_2O$ for the monohydrate). Desvenlafaxine succinate monohydrate has a molecular weight of 399.48, and the following structural formula:



Desvenlafaxine succinate is prepared as a white to off-white powder that is soluble in water (pH dependent), with an octanol:aqueous system (at pH 7.0) partition coefficient of 0.21. The approved product is formulated as an extended release tablet for once daily oral administration, and is available in tablet strengths of 50 mg and 100 mg. Each PRISTIQ™ tablet contains either 76 mg or 152 mg of desvenlafaxine succinate monohydrate, which is equivalent to 50 mg or 100 mg, respectively, of desvenlafaxine.

2. A Complete Identification Of The Federal Statute Including The Applicable Provisions Of Law Under Which The Regulatory Review Occurred

The approved product, PRISTIQ™, was subject to regulatory review under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §355).

3. An Identification Of The Date On Which The Product Received Permission For Commercial Marketing Or Use Under The Provision Of Law Under Which The Applicable Regulatory Review Period Occurred

The approved product, PRISTIQ™, received permission for commercial marketing or use under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §355) on February 29, 2008. A copy of a letter from the Food and Drug Administration ("FDA") indicating the date of approval is attached hereto at **Exhibit B**.

4. In The Case Of A Drug Product, An Identification Of Each Active Ingredient In The Product And As To Each Active Ingredient, A Statement That It Has Not Been Previously Approved For Commercial Marketing Or Use Under The Federal Food, Drug, and Cosmetic Act, The Public Health Service Act, Or The Virus-Serum-Toxin Act, Or A Statement Of When The Active Ingredient Was Approved For Commercial Marketing Or Use (Either Alone Or In Combination With Other Active Ingredients), The Use For Which It Was Approved, And The Provision Of Law Under Which It Was Approved

The active ingredient in PRISTIQ™ is desvenlafaxine succinate, which has not been previously approved for commercial marketing or use under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act.

5. A Statement That The Application Is Being Submitted Within The Sixty Day Period Permitted For Submission Pursuant to 37 CFR §1.720(f) And An Identification Of The Date Of The Last Day On Which The Application Could Be Submitted

This application is being submitted within the permitted sixty (60) day period, the last day of which is April 28, 2008.

6. A Complete Identification Of The Patent For Which An Extension Is Being Sought By The Name Of The Inventor, The Patent Number, The Date Of Issue, And The Date Of Expiration

The complete identification of the patent for which extension is sought is:

Inventors:	Anthony F. Hadfield Syed M. Shah Michael W. Winkley Karen W. Sutherland James A. Provost Aeri Park Rex A. Shiplett Brenton W. Russell Beat T. Weber
Patent Number:	6,673,838
Issue Date:	January 6, 2004
Expiration Date:	February 11, 2022 (without extension under 35 U.S.C. §156)

7. A Copy Of The Patent For Which An Extension Is Being Sought, Including The Entire Specification (Including Claims) And Drawings

A complete copy of U.S. Patent No. 6,673,838 is annexed as **Exhibit C**.

8. A Copy Of Any Disclaimer, Certificate of Correction, Receipt Of Maintenance Fee Payment, Or Reexamination Certificate Issued In The Patent

The patent for which extension is being sought has not been the subject of any disclaimer, certificate of correction, or reexamination certificate. The first maintenance fee was duly paid on June 21, 2007 by Applicant, and no additional maintenance fees are due at this time. A copy of the maintenance fee statement evidencing this status is annexed as **Exhibit D**.

9. A Statement That The Patent Claims The Approved Product Or A Method Of Using Or Manufacturing The Approved Product, And A Showing Which Lists Each Applicable Patent Claim And Demonstrates The Manner In Which At Least One Such Patent Claim Reads On The Approved Product Or Method Of Using Or Manufacturing The Approved Product

U.S. Patent No. 6,673,838 claims the approved product, PRISTIQ™. More specifically, claims 1-7 and 22 read on the approved product and claim the active ingredient of the final approved product desvenlafaxine succinate, claims 23, 25-34, and 46 read on the approved product and claim pharmaceutical compositions comprising desvenlafaxine succinate, and claims 35 and 45 read on a methods that comprise using desvenlafaxine succinate for treatment. Claim 1 is compared to the approved product in the table below.

Patent Claim	Approved Product
1. A compound which is O-desmethyl venlafaxine succinate.	The active ingredient of the approved product is desvenlafaxine succinate, which is also known as and is identical to O-desmethyl venlafaxine succinate.

10. A Statement, Beginning On A New Page, Of The Relevant Dates And Information Pursuant To 35 U.S.C. § 156(g) In Order To Enable The Secretary Of Agriculture, As Appropriate, To Determine The Applicable Regulatory Review Period As Follows (i): For A Patent Claiming A Human Drug Product, Antibiotic, Or Human Biological Product, The Effective Date Of The Investigational New Drug (IND) Application And The IND Number; The Date On Which A New Drug Application (NDA) Or A Product License Application (PLA) Was Initially Submitted And The NDA Or PLA Number And The Date On Which The NDA Was Approved Or The Product License Issued

Wyeth was notified via teleconference with the FDA on May 9, 2002 that that the IND (IND 64,552) for desvenlafaxine succinate was in effect, and received a letter from the FDA confirming the IND became effective on June 11, 2002. For purposes of this application for patent term extension, the Applicant is entitled to an IND date of at least as early as June 11, 2002. The NDA (NDA 21-966) for PRISTIQ™ was initially submitted to the Food and Drug Administration on December 22, 2005 and was approved on February 29, 2008.

11. A Brief Description Beginning On A New Page OF The Significant Activities Undertaken By The Marketing Applicant During The Applicable Regulatory Review Period With Respect To The Approved Product And The Significant Dates Applicable To Such Activities

A brief description of significant activities undertaken by the marketing applicant during the regulatory review period with respect to the approved product in annexed as **Exhibit E**. This exhibit provides a chronology of the major communications between the marketing applicant and the Food and Drug Administration, including a brief summary of the subject matter and date of these communications.

Applicant reserves the right to supplement the chronology of **Exhibit E** with materials from which it was derived or other evidence related to Applicant's conduct in obtaining the approval of PRISTIQ™. *See, e.g.*, 21 CFR § 60.32.

12. A Statement Beginning On A New Page That In The Opinion Of The Applicant The Patent Is Eligible For The Extension And A Statement As To The Length Of The Extension Claimed, Including How The Length Of Extension Was Determined

Applicant is of the opinion that U.S. Patent No. 6,673,838 is eligible for extension under 35 U.S.C. § 156, because it satisfies all of the requirements for such extension as follows:

a. 35 U.S.C. §156(a); 37 CFR §1.720(a)

U.S. Patent No. 6,673,838 claims a product, and a method of using a product.

b. 35 U.S.C. §156(a)(1); 37 CFR §1.720(g)

The term of U.S. Patent No. 6,673,838 has not expired before submission of this application.

c. 35 U.S.C. §156(a)(2); 37 CFR §1.720(b)

The term of U.S. Patent No. 6,673,838 has never previously been extended under 35 U.S.C. §156.

d. 35 U.S.C. §156(a)(3); 37 CFR §1.730

This application for extension is submitted by the authorized agent or the owner of record in accordance with the requirement of 35 U.S.C. §156(d) and the rules of the U.S. Patent and Trademark Office.

e. 35 U.S.C. §156(a)(4); 37 CFR §1.720(d)

The product PRISTIQ™ has been subject to a regulatory review period as defined in 35 U.S.C. §156(g) before its commercial marketing or use.

f. 35 U.S.C. §156(a)(5)(A); 37 CFR §1.720(e)(i)

The commercial marketing or use of the product PRISTIQ™ after the regulatory review period is the first permitted commercial marketing or use of the product under the provision of the Federal Food, Drug, and Cosmetics Act (21 U.S.C. §360) under which such regulatory review period occurred.

g. 35 U.S.C. §156(c)(4); 37 CFR §1.720(h)

No other patent has been extended for the same regulatory review period for the product PRISTIQ™.

h. 35 U.S.C. §156(d)(1); 37 CFR §1.720(f)

This application is submitted within the permitted 60 day period beginning on the date the product first received permission for commercial marketing or use.

Applicant is of the opinion that U.S. Patent No. 6,673,838 is eligible for extension under 35 U.S.C. § 156 for 17 days, as determined pursuant to 37 CFR §1.775 as follows:

Patent Information:

Patent Issue Date	January 6, 2004
Earliest non-provisional priority date	February 11, 2002
Days Extension under 35 U.S.C. 154(b)	0

FDA Information:

Latest Date IND Becomes Effective	June 11, 2002
Date NDA Submitted to the FDA	December 22, 2005
Date NDA Approved by the FDA	February 29, 2008

IND Period:

Latest Start Date of Regulatory Review Period	June 11, 2002
IND Review Period (days)	1290
½ IND Review Period (days)	645

Regulatory Review Period Allowed:

NDA Review Period (days)	800
Regulatory Review Period (days)	2090
Reg. Rev. Period less ½ IND period (days)	1445

Statutory Limitations:

Patent Expiration Date (20 year term)	February 11, 2022
Expiration under 5 year extension limitation (Date 1)	February 11, 2027
Expiration under 14 from NDA approval limitation (Date 2)	February 28, 2022
Expiration based upon full review period (Date 3)	January 26, 2026
Final Expiration Date (Earliest of Date 1, Date 2, or Date 3)	February 28, 2022
Maximum Extension in Days:	**17**

13. A Statement That Applicant Acknowledges A Duty To Disclose To The Commissioner Of Patents And Trademarks And The Secretary Of Health And Human Services Any Information Which Is Material To The Determination Of Entitlement To The Extension Sought

Applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services any information which is material to any determinations of entitlement to the extension sought in the Application.

14. The Prescribed Fee For Receiving And Acting Upon The Application For Extension

The prescribed fee pursuant to 37 CFR §1.20(j) for receiving and acting upon this application is to be charged to the Deposit Account of Applicant's undersigned attorney as authorized in the attached letter, which is submitted in triplicate.

15. The Name, Address, And Telephone Number Of The Person To Whom Inquiries And Correspondence Relating To The Application For Patent Term Extension Are To Be Directed

Please address all correspondence to:

Kevin G. Shaw

Hogan & Hartson, LLP

555 Thirteenth St., NW

Washington, DC 20004

16. A Duplicate Of The Application Papers, Certified As Such

Applicant hereby certifies that this application for extension is being filed in triplicate.

17. An Oath Or Declaration

Applicant, through its undersigned patent attorney authorized to practice before the Patent and Trademark Office and who has general authority from the agent or owner to act on behalf of the agent or owner in patent matters, being duly warned that willful false statements are punishable by fine or imprisonment or both under section 1001 of Title 18, United States Code and that willful false statements and the like may jeopardize the validity of this application and the patent to which it relates, states and declares that the following statements made based on his own knowledge are true and that all statements made on information and belief are believed to be true:

(1) The undersigned is registered to practice before the Patent and Trademark Office and is making this declaration as a patent attorney who has general authority to act on behalf of the applicant in patent matters.

(2) The undersigned has reviewed and understands the contents of the application being submitted pursuant to this section;

(3) The undersigned believes the patent is subject to an extension pursuant to 37 C.F.R. § 1.710 in the event of NDA approval and, in the interim, is subject to an extension pursuant to 37 C.F.R. § 1.790;

(4) The undersigned believes an extension of the length claimed is justified under 35 U.S.C. 156 and the applicable regulations; and

(5) The undersigned believes the patent for which extension is being sought meets the conditions for extension of the term of a patent as set forth in 37 C.F.R. § 1.720 in the event of NDA approval, and meets the requirements for an interim extension of a patent set forth in 37 C.F.R. § 1.790.

If this application for extension of patent term is held to be informal, applicant may seek to have that holding reviewed by filing a petition with the required fee, as necessary, pursuant to 37 C.F.R. §§ 1.181, 1.182 or 1.183, as appropriate, within such time as may be set in any notice that the application has been held to be informal, or if no time is set, within one month of the date on which the application was held informal.

Respectfully submitted,

Dated: April 25, 2008

By: _____
Kevin G. Shaw
Registration No. 43,110

HOGAN & HARTSON LLP
555 13th Street, N.W.
Washington, D.C. 20004
Telephone: 202-637-5600
Facsimile: 202-637-5910
Email: kgshaw@hhlaw.com
Customer No.: 24633

Exhibit A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 6,673,838
Inventors: HADFIELD, Anthony F. et al.
Issue Date: January 6, 2007
For: SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE
Assignee: Wyeth

POWER OF ATTORNEY FOR PATENT TERM EXTENSION APPLICATION

Wyeth, a corporation organized and existing under the laws of Delaware, and having a principal place of business at 5 Giralda Farms, Madison, NJ 07490, is the sole owner of the entire interest in and to U.S. Patent No. 6,673,838 as reflected in the various assignment documents recorded by the U.S. Patent and Trademark Office on August 27, 2001 at Reel 012126, Frame 0893, on August 27, 2001 at Reel 012127, Frame 0102, on April 12, 2002 at Reel 012828, Frame 0928, on July 30, 2002 at Reel 013121, Frame 0837, on July 30, 2002 at Reel 013121, Frame 0855, on July 31, 2002 at Reel 013127, Frame 0287, on July 31, 2002 at Reel 013127, Frame 0306, on August 1, 2002 at Reel 013130, Frame 0479, and on August 21, 2002 at Reel 013229, Frame 0864.

Wyeth hereby revokes all previous powers of attorney and appoints Kevin G. Shaw and the registered practitioners of Hogan & Hartson, L.L.P. included in the Customer Number provided below to prosecute this patent term extension application and to transact all business in the Patent and Trademark Office connected therewith, and further directs that all correspondence be addressed to Kevin G. Shaw at that Customer Number.

The undersigned, acting in the official capacity stated below, has authority to does hereby execute this document on behalf of Wyeth.

Customer Number: 24633

Please direct all inquiries to:

Kevin G. Shaw
Telephone: (202) 637-6466
Facsimile: (202) 637-5910

William King
Assistant Secretary
Wyeth
5 Giralda Farms
Madison, NJ 07490

24/Apr./2008
Date

Exhibit B

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-992

NDA APPROVAL

Wyeth Pharmaceuticals, Inc.
Attention: Kenneth Bonk
Director II, Global Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-9822

Dear Mr. Bonk:

Please refer to your new drug application (NDA) dated and received on December 22, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pristiq (desvenlafaxine succinate) 50mg, and 100mg extended release tablets.

We acknowledge receipt of your submissions dated:

April 4, 2007	December 14, 2007	February 14, 2008
May 11, 2007	December 19, 2007	February 15, 2008
June 1, 2007	December 20, 2007	February 20, 2008
June 27, 2007	January 14, 2008	February 21, 2008
August 23, 2007	February 4, 2008	February 22, 2008
August 29, 2007	February 11, 2008	

The August 29, 2007 submission constituted a complete response to our January 22, 2007 action letter.

This new drug application provides for the use of Pristiq (desvenlafaxine succinate) tablets for the treatment of major depressive disorder.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert and Medication Guide). Upon receipt, we will transmit that version to the

National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 21-992."

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the submitted carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005).* Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 21-992.**" Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PEDIATRIC RESEARCH EQUITY ACT (PREA)

All applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are waiving the pediatric study requirement for ages 0-6 years because the necessary studies are impossible or highly impracticable because there are not enough patients in that age group with the disease to study. We are deferring submission of your pediatric studies for ages 7-17 years because the drug is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of these postmarketing studies shall be reported annually according to 21 CFR 314.81. These commitments are listed below.

POSTMARKETING COMMITMENTS

We remind you of your following postmarketing study commitments agreed upon in your submission dated February 19, 2008. These commitments are listed below.

1. Deferred Pediatric Studies Under PREA

   You have agreed to conduct studies to assess the safety and effectiveness of desvenlafaxine succinate as a treatment for Major Depressive Disorder in pediatric patients ages 7 to 17 (children and adolescents). Both children (ages 7 to 11 years) and adolescents (ages 12 to 17 years) will be equally represented in the samples, and there will be a reasonable distribution of both sexes in these age strata. You have agreed to submit the results of these studies no later than 4.5 years after the date of approval for this NDA.

   Final Report Submission: 4.5 years from the date of approval

Submit final study reports to this NDA. For administrative purposes, all submissions related to this/these pediatric postmarketing study commitment(s) must be clearly designated "**Required Pediatric Study Commitments**".

2. Exploration of Dose Response for Effectiveness

Your NDA for desvenlafaxine succinate (DVS) demonstrates the effectiveness of doses as low as 50 mg as a treatment for Major Depressive Disorder (MDD), however, the available data for effectiveness for this drug in MDD suggests a flat dose response curve for efficacy between 50 and 400 mg/day. On the other hand, there is a clear dose response for adverse events as the dose increases from 50 to 400 mg/day. Therefore, there is a need to better understand the lower end of the dose response curve to determine if efficacy might be achieved at doses even lower than 50 mg/day. You have agreed to conduct and submit the results of a randomized controlled study including placebo and DVS doses of 10, 25, and 50 mg/day as a Postmarketing commitment. This study will assess efficacy in this dose range and will also include a validated and reliable outcome measure to assess for sexual dysfunction. You have agreed to submit the results of this trial no later than 3 years after the date of the approval for this NDA.

Final Report Submission: 3 years from the date of approval

3. Long-Term Efficacy Studies

Although your NDA for desvenlafaxine succinate demonstrates effectiveness of recommended doses (50-100 mg/day) as a treatment for Major Depressive Disorder over an interval of 8 weeks, it does not provide information about the duration and conditions of treatment with desvenlafaxine that are necessary to sustain its antidepressant effects over the full duration (likely 6 months to a year or longer) of an acute major depressive episode at these same recommended doses. While it is widely assumed that continued treatment of symptomatically remitted patients reduces their risk of relapse, [redacted] we have no evidence that desvenlafaxine at these lower doses has efficacy after 8 weeks. Once you have established the lower end of the dose-response curve for efficacy, you have agreed to conduct and submit the results of a randomized withdrawal study to address longer-term efficacy for your drug at appropriate doses. If the lower dose study establishes that 50 mg/day is the lowest effective dose, this study will evaluate doses of 50 and 100 mg/day. You have agreed to submit the results of this trial no later than 3 years after the date of initiation, or approximately 5.5 years from the date of approval for this NDA..

Final Report Submission: 5.5 years from the date of approval

4. Sexual Dysfunction

While it is clear that desvenlafaxine has a qualitatively negative effect on sexual function from the adverse events collected during your earlier trials, we do not have quantified sexual dysfunction data. You have agreed to assess sexual dysfunction in your planned lower dose study. If the lower dose study establishes that 50 mg/day is the lowest effective dose, you have

agreed to conduct another acute, randomized controlled trial with placebo, 50, and 100 mg/day, and employ a validated and reliable outcome measure to assess for sexual dysfunction. This study could be conducted in parallel with the longer-term efficacy trial, and the results could be submitted approximately 5.5 years from the date of approval for this NDA.

Final Report Submission: 5.5 years from the date of approval

5. Pharmacology/Toxicology

Your combined fertility and embryo-fetal toxicity study in rats did not adequately assess desvenlafaxine's potential for embryo-fetal toxicity, including teratogenicity, due to decreased number of fetuses available for analysis at the high dose of 300 mg/kg. This appeared to result from effects of desvenlafaxine on fertility and pre-implantation loss and would not be factors if dosing were only done during the period of organogenesis. Consequently, you have agreed to conduct a standard embryo-fetal toxicity study in rats, and submit the results no later than 3 years after the date of the approval for this NDA.

Final Report Submission: 3 years from the date of approval

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments should be prominently labeled "**Postmarketing Study Commitment Protocol**", "**Postmarketing Study Commitment Final Report**", or "**Postmarketing Study Commitment Correspondence.**"

DISSOLUTION METHOD AND SPECIFICATION

Method:

Apparatus:	USP Apparatus 1 (baskets)
Speed:	100 rpm
Medium:	900 mL 0.9% NaCl in water
Temperature:	$37^0C \pm 0.5^0C$

Specification:

Time	Criteria (% LC Released)
2 hours	
4 hours	
8 hours	
12 hours	
24 hours	

EXPIRY DATE

An expiration of 24 months has been granted.

ADVISORY COMMITTEE

NDA 21-992 was not referred to an advisory committee for review because there are several previously approved agents in the antidepressant class of drugs, evaluation of the safety data did not reveal particular safety issues that were unexpected for this class, and the design and results of the efficacy trials did not pose particular concerns.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call Renmeet Grewal, Pharm.D., Regulatory Project Manager, at (301) 796-1080.

Sincerely,

{See appended electronic signature page}

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Label & Medguide

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Temple

2/29/2008 03:15:15 PM

Exhibit C

Exhibit D

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Customer No 25291

ISTMT

DATE PRINTED
04/23/2008

WYETH
PATENT LAW GROUP
5 GIRALDA FARMS
MADISON NJ 07940

MAINTENANCE FEE STATEMENT

According to the records of the U.S.Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O.Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
6,673,838	**$900.00**	**$0.00**	**06/21/07**	**10/073,743**	**01/06/04**	**02/11/02**	**04**	**NO**	**AM-100463**

Exhibit E

Exhibit E

A brief description of significant activities undertaken by Wyeth during the regulatory review period for PRISTIQ™, together with applicable dates, follows below. A more detailed description of activities undertaken by Wyeth, including those listed below, is set forth in the IND Activities and NDA Activities tables produced on the pages following part 4 of this Exhibit.

1. Between June 11, 2002 and December 22, 2005, Wyeth conducted multiple clinical studies of PRISTIQ™. There were seven randomized, double-blind, placebo-controlled, fixed- and flexible-dose studies, one relapse prevention study, and three open-label, long-term safety studies. Wyeth also conducted at least 15 pharmacokinetic and pharmacodynamic studies.

2. Key Regulatory Dates

April 12, 2002	IND 64,552 submitted to FDA
May 9, 2002	FDA notification (via telephone) that IND is in effect
June 11, 2002	FDA letter confirming IND is in effect
February 4, 2003	Pre-Phase III meeting with FDA
April 10, 2003	End-of-Phase II/CMC meeting with FDA
November 6, 2003	Type C Meeting with FDA re: IVIVC
June 15, 2005	Meeting with FDA re: CMC Quality by Design (QbD)
September 20, 2005	Type C Meeting with FDA: CMC Pilot Program
September8, 2005	Pre-NDA meeting with FDA
October 27, 2005	Pre-NDA meeting with FDA re: CMC Issues
December 22, 2005	NDA 21-992 submitted to FDA
January 22, 2007	FDA action letter ("approvable")
August 29, 2007	Complete response to FDA action letter
February 29, 2008	FDA approval

3. Summary of Phase III Clinical Studies

There were seven randomized, double-blind, placebo-controlled, fixed- and flexible-dose studies, one relapse prevention study, and three open-label, long-term safety studies.

Start	**Stop**	**Study** (n=patients randomized)
September 2002	March 2003	Fixed-Dose Efficacy (n=227)
June 2003	August 2005	Relapse Prevention (n=603)
June 2003	May 2004	Flexible-Dose Efficacy (n=247)
August 2003	March 2006	Open-Label Flexible-Dose Safety (n=1408)
November 2003	November 2004	Fixed-Dose Efficacy (n=480)
November 2003	September 2004	Fixed-Dose Efficacy (n=375)
January 2004	May 2005	Open-Label Flexible-Dose Safety (n=108)
March 2004	May 2005	Flexible-Dose Efficacy (n=369)
April 2004	March 2005	Flexible-Dose Efficacy (n=369)
July 2004	May 2005	Flexible-Dose Efficacy (n=244)
October 2004	October 2005	Open-Label Flexible-Dose Safety (n=52)

4. Following the initial submission of the NDA on December 22, 2005, Wyeth submitted additional information to FDA on the following dates:

February 1, 2006
February 14, 2006
February 16, 2006
March 7, 2006
March 16, 2006
April 21, 2006
April 28, 2006
May 10, 2006
June 7, 2006
June 9, 2006
June 26, 2006
July 3, 2006
July 13, 2006
July 31, 2006
August 31, 2006
September 5, 2006
September 14, 2006
September 22, 2006
September 26, 2006
October 10, 2006
October 12, 2006
October 26, 2006
November 1, 2006
December 8, 2006
January 25, 2007
February 2, 2007
April 4, 2007
May 11, 2007
June 1, 2007
June 27, 2007
August 23, 2007
August 29, 2007
December 13, 2007
December 14, 2007
December 19, 2007
December 20, 2007
January 14, 2008
February 4, 2008
February 11, 2008
February 14, 2008
February 15, 2008
February 20, 2008
February 21, 2008
February 22, 2008
February 29, 2008

Grits Doc ID	App. Country	Doc. Date	Reference #	Doc. Type	Sub1 Type	Sub2 Type	Sub3 Type	Chronology Description	Reg. Link	Email Date	Protocol	Import Country	To	From	App. #	App. Description	App. Region	Corporate Tradename	App. Country Abbrev.
106612	UNITED STATES	12-Apr-02	0	IDA-Initial							0600D3-171-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105132	UNITED STATES	25-Apr-02	1	IA Correspondence	Response to	Information Request		Current Specifications & Test Methods of Venlafaxine HCL					FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105168	UNITED STATES	26-Apr-02	2	IA Correspondence	Response to	Information Request							FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105166	UNITED STATES	26-Apr-02	2	IA Correspondence	CMC Issues	Info Request-Respon							FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105353	UNITED STATES	1-May-02	3	IA Correspondence	Response to	Information Request							FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105458	UNITED STATES	6-May-02	4	IA Correspondence	Response to	Information Request							FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105516	UNITED STATES	6-May-02	5	IA Correspondence	Response to	Information Request							FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
106639	UNITED STATES	5-Jun-02	6	IA Correspondence	Prot Amend	Change in Prot					0600D3-171-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
107202	UNITED STATES	17-Jun-02	7	IA Correspondence	Prot Amend	Change in Prot					0600D3-171-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
107460	UNITED STATES	20-Jun-02	8	IA Correspondence	Request	Review/Comment		Toxicology and Drug Metabolism Support for Phase 3 Clinical Studies					FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
107789	UNITED STATES	25-Jun-02	9	IA Correspondence	Info Amend-Pharm/Tox								FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
108208	UNITED STATES	1-Jul-02	10	IA Correspondence	Info Amend-CMC								FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
108210	UNITED STATES	1-Jul-02	11	IA Correspondence	Prot Amend	New Protocol		New Protocol - Protocol No. 0600D3-186-US - DVS-233 SR - IND No 64,552			0600D3-186-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
108212	UNITED STATES	1-Jul-02	12	IA Correspondence	Prot Amend	New Protocol		DVS-233 SR - IND No. 64,552 - New Protocol #0600D3-223-US			0600D3-223-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
108213	UNITED STATES	1-Jul-02	13	IA Correspondence	Prot Amend	New Protocol		New Protocol - DVS-233 SR - IND No. 64,552 - New Protocol #0600D3-223-PL			0600D3-223-PL		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
108683	UNITED STATES	10-Jul-02	14	IA Correspondence	Prot Amend	Change in Prot					0600D3-223-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
110363	UNITED STATES	13-Aug-02	15	IA Correspondence	Prot Amend	Change in Prot					0600D3-223-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
110543	UNITED STATES	15-Aug-02	16	IA Correspondence	Prot Amend	Change in Prot					0600D3-223-PL		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
110575	UNITED STATES	16-Aug-02	17	IA Correspondence	Prot Amend	Add Invest		S:\CNS\FDA\Dvs-233 SR\IND\S017.doc			0600D3-223-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
110575	UNITED STATES	16-Aug-02	17	IA Correspondence	Prot Amend	Del Subinvest		S:\CNS\FDA\Dvs-233 SR\IND\S017.doc			0600D3-223-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

110575 UNITED STATES	16-Aug-02	17 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S017.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
110816 UNITED STATES	28-Aug-02	18 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S019.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
111000 UNITED STATES	30-Aug-02	19 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S020.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
111274 UNITED STATES	9-Sep-02	20 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
111311 UNITED STATES	11-Sep-02	21 IA Correspondence	Info Amend-Pharm/Tox		S:\CNS\FDA\Dvs-233 SR\IND\S022.doc		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
112048 UNITED STATES	26-Sep-02	22 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
112178 UNITED STATES	2-Oct-02	23 IA Correspondence	Prot Amend	New Protocol		0600D3-172-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
112230 UNITED STATES	3-Oct-02	24 IA Correspondence	Prot Amend	Change in Prot		0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Info Amend-Clin	IRB - Add	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Prot Amend	Add Subinvest	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Info Amend-Clin	IRB - Delete	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Prot Amend	Del Subinvest	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Prot Amend	Add Invest	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113447 UNITED STATES	1-Nov-02	26 IA Correspondence	Prot Amend	Change in Prot		0600D3-223-PL	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113474 UNITED STATES	1-Nov-02	27 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113880 UNITED STATES	14-Nov-02	28 IA Correspondence	Prot Amend	Add Subinvest	Desvenlafaxine Succinate (DVS-233) Protocol No. 0600D3-223-US	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113880 UNITED STATES	14-Nov-02	28 IA Correspondence	Prot Amend	Del Subinvest	Desvenlafaxine Succinate (DVS-233) Protocol No. 0600D3-223-US	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113880 UNITED STATES	14-Nov-02	28 IA Correspondence	Prot Amend	Name Change	Desvenlafaxine Succinate (DVS-233) Protocol No. 0600D3-223-US	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

114110 UNITED STATES	15-Nov-02	29 IA Correspondence	Prot Amend	New Protocol		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
114111 UNITED STATES	19-Nov-02	30 IA Correspondence	Meeting/Telecon	Meeting-Request	Request for Pre-Phase 3 Mtg		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
114227 UNITED STATES	21-Nov-02	31 IA Correspondence	Prot Amend	Add Invest		0600D3-223-PL	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
114227 UNITED STATES	21-Nov-02	31 IA Correspondence	Prot Amend	Add Subinvest		0600D3-223-PL	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
114334 UNITED STATES	26-Nov-02	32 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
114571 UNITED STATES	6-Dec-02	33 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
114994 UNITED STATES	20-Dec-02	34 IA Correspondence	Prot Amend	Change in Prot		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115025 UNITED STATES	20-Dec-02	35 IA Correspondence	Non-Clinical Issues	Other			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115026 UNITED STATES	23-Dec-02	36 IA Correspondence	Meeting/Telecon	Backgrnd Pkg-Submm	re: Pre-Phase 3 Meeting		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115605 UNITED STATES	6-Jan-03	37 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115607 UNITED STATES	13-Jan-03	38 IA Correspondence	Info Amend-Clin	Name Change	FDA Submission - DVS-233 SR - SRA01A04\DATA\SHARED\CNS\FDA\Dvs-233 SR\IND\S040.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115607 UNITED STATES	13-Jan-03	38 IA Correspondence	Prot Amend	Del Subinvest	FDA Submission - DVS-233 SR - SRA01A04\DATA\SHARED\CNS\FDA\Dvs-233 SR\IND\S040.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115607 UNITED STATES	13-Jan-03	38 IA Correspondence	Prot Amend	Add Subinvest	FDA Submission - DVS-233 SR - SRA01A04\DATA\SHARED\CNS\FDA\Dvs-233 SR\IND\S040.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
115848 UNITED STATES	16-Jan-03	39 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116114 UNITED STATES	28-Jan-03	40 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116131 UNITED STATES	29-Jan-03	41 IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116239 UNITED STATES	31-Jan-03	42 IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116325 UNITED STATES	14-Feb-03	43 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116325 UNITED STATES	14-Feb-03	43 IA Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

116368 UNITED STATES	19-Feb-03	44 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116368 UNITED STATES	19-Feb-03	44 IA Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116805 UNITED STATES	21-Feb-03	45 IA Correspondence	Info Amend-Pharm/Tox		S:\CNS\FDA\Dvs-233 SR\IND\S047.doc		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116837 UNITED STATES	21-Feb-03	46 IA Correspondence	Safety Rpt: Clin	Init Writ\Follow-up	33 year-old male experienced a "partial (focal) seizure .		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116859 UNITED STATES	24-Feb-03	47 IA Correspondence	Meeting/Telecon	Meeting-Request	Request for EOP2 CMC Meeting		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116878 UNITED STATES	24-Feb-03	48 IA Correspondence	Info Amend-Clin	IRB - Add	S:\CNS\FDA\Dvs-233 SR\IND\S048.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116878 UNITED STATES	24-Feb-03	48 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S048.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116878 UNITED STATES	24-Feb-03	48 IA Correspondence	Info Amend-Clin	IRB - Delete	S:\CNS\FDA\Dvs-233 SR\IND\S048.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
116878 UNITED STATES	24-Feb-03	48 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S048.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117012 UNITED STATES	27-Feb-03	49 IA Correspondence	Meeting/Telecon	Minutes			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117028 UNITED STATES	3-Mar-03	50 IA Correspondence	Prot Amend	New Protocol		0600D3-190-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117646 UNITED STATES	13-Mar-03	51 IA Correspondence	Meeting/Telecon	Backgrnd Pkg-Submm	Pkg for April 10 EOP2 CMC Meeting		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117647 UNITED STATES	13-Mar-03	52 IA Correspondence	Meeting/Telecon	Backgrnd Pkg-Submm			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117647 UNITED STATES	13-Mar-03	52 IA Correspondence	Meeting/Telecon	Request-Response			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
118061 UNITED STATES	20-Mar-03	53 IA Correspondence	Meeting/Telecon	Backgrnd Pkg-Submm	CMC EOP2 Additional Info Requested		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
118064 UNITED STATES	20-Mar-03	54 IA Correspondence	Meeting/Telecon	Info			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
118064 UNITED STATES	20-Mar-03	54 IA Correspondence	Meeting/Telecon	Request-Response			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
118852 UNITED STATES	1-Apr-03	55 IA Correspondence	Info Amend-Pharm/Tox		S:\CNS\FDA\Dvs-233 SR\IND\S053.doc		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
119870 UNITED STATES	8-Apr-03	56 IA Correspondence	Annual Report-IDA	Subm	Annual Report - S:\CNS\FDA\Dvs-233 SR\IND\S051.doc		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
119249 UNITED STATES	8-Apr-03	57 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S054.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

119249 UNITED STATES	8-Apr-03	57 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S054.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119759 UNITED STATES	21-Apr-03	58 IA Correspondence	Meeting/Telecon	Minutes	EOP2 April 10 CMC Meeting Minutes		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119951 UNITED STATES	24-Apr-03	59 IA Correspondence	Info Amend-CMC		Addition of Guayama PR and film coat		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119954 UNITED STATES	24-Apr-03	60 IA Correspondence	Prot Amend	New Protocol		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119962 UNITED STATES	25-Apr-03	61 IA Correspondence	Prot Amend	New Protocol		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119977 UNITED STATES	28-Apr-03	62 IA Correspondence	Prot Amend	New Protocol		3151A1-308-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
120488 UNITED STATES	1-May-03	63 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121145 UNITED STATES	9-May-03	64 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121217 UNITED STATES	14-May-03	65 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121466 UNITED STATES	16-May-03	66 IA Correspondence	Prot Amend	New Protocol		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121488 UNITED STATES	16-May-03	67 IA Correspondence	Prot Amend	New Protocol		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121503 UNITED STATES	16-May-03	68 IA Correspondence	Prot Amend	Change in Prot		0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
122331 UNITED STATES	29-May-03	69 IA Correspondence	Request	Review/Comment	Response to FDA Comments Rec'd during Feb 04 2003 Pre-Phase 3 Mtg		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
122425 UNITED STATES	4-Jun-03	70 IA Correspondence	Prot Amend	Change in Prot		0600D3-223-PL	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123088 UNITED STATES	18-Jun-03	71 IA Correspondence	Info Amend-Clin	Research Facil-Del		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123088 UNITED STATES	18-Jun-03	71 IA Correspondence	Info Amend-Clin	IRB - Add		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123088 UNITED STATES	18-Jun-03	71 IA Correspondence	Prot Amend	Add Invest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123088 UNITED STATES	18-Jun-03	71 IA Correspondence	Info Amend-Clin	IRB - Delete		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123096 UNITED STATES	18-Jun-03	72 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123297 UNITED STATES	23-Jun-03	73 IA Correspondence	Info Amend-Clin	Research Facil - Add	S:\CNS\FDA\Dvs-233 SR\IND\S068.doc	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

123297 UNITED STATES	23-Jun-03	73 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S068.doc	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
123297 UNITED STATES	23-Jun-03	73 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S068.doc	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
123521 UNITED STATES	26-Jun-03	74 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125232 UNITED STATES	23-Jul-03	75 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125577 UNITED STATES	29-Jul-03	76 IA Correspondence	Prot Amend	Add Subinvest	Submission provides for addition/deletion of subinvestigators for Protocol No. 0600D3-223-US.	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125577 UNITED STATES	29-Jul-03	76 IA Correspondence	Prot Amend	Del Subinvest	Submission provides for addition/deletion of subinvestigators for Protocol No. 0600D3-223-US.	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125617 UNITED STATES	29-Jul-03	77 IA Correspondence	Gen Corr		Rationale Designation Starting Material		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125632 UNITED STATES	1-Aug-03	78 IA Correspondence	Info Amend-Clin	Address Change		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125632 UNITED STATES	1-Aug-03	78 IA Correspondence	Prot Amend	Add Invest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126374 UNITED STATES	11-Aug-03	79 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S077.doc	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126374 UNITED STATES	11-Aug-03	79 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S077.doc	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126506 UNITED STATES	14-Aug-03	80 IA Correspondence	Prot Amend	Change in Prot		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126875 UNITED STATES	21-Aug-03	81 IA Correspondence	Info Amend-Clin	Name Change	S:\CNS\FDA\Dvs-233 SR\IND\S079.doc	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126875 UNITED STATES	21-Aug-03	81 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S079.doc	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126950 UNITED STATES	25-Aug-03	82 IA Correspondence	Info Amend-CMC				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126966 UNITED STATES	26-Aug-03	83 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126967 UNITED STATES	27-Aug-03	84 IA Correspondence	Prot Amend	New Protocol		3151A1-174-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127331 UNITED STATES	3-Sep-03	85 IA Correspondence	Prot Amend	Change in Prot		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127331 UNITED STATES	3-Sep-03	85 IA Correspondence	Response to	Other			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127433 UNITED STATES	4-Sep-03	86 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S084.doc	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

127433 UNITED STATES	4-Sep-03	86 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S084.doc	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127549 UNITED STATES	5-Sep-03	87 IA Correspondence	Prot Amend	Change in Prot		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127550 UNITED STATES	5-Sep-03	88 IA Correspondence	Prot Amend	Change in Prot		3151A1-308-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127601 UNITED STATES	8-Sep-03	89 IA Correspondence	Prot Amend	Change in Prot		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127620 UNITED STATES	9-Sep-03	90 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\DVS-233 SR\IND\S087.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127620 UNITED STATES	9-Sep-03	90 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\DVS-233 SR\IND\S087.doc	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127638 UNITED STATES	9-Sep-03	91 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S088.doc	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127638 UNITED STATES	9-Sep-03	91 IA Correspondence	Prot Amend	Del Invest	S:\CNS\FDA\Dvs-233 SR\IND\S088.doc	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127704 UNITED STATES	11-Sep-03	92 IA Correspondence	Meeting/Telecon	Meeting-Request	Requesting a Type C Meeting with Agency		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127712 UNITED STATES	11-Sep-03	93 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S090.doc	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127712 UNITED STATES	11-Sep-03	93 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S090.doc	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127714 UNITED STATES	11-Sep-03	94 IA Correspondence	Prot Amend	Add Invest	S:\CNS\FDA\Dvs-233 SR\IND\S089.doc Submission provides for a new investigator and the addition/deletion of subinvestigators.	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127714 UNITED STATES	11-Sep-03	94 IA Correspondence	Prot Amend	Del Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S089.doc Submission provides for a new investigator and the addition/deletion of subinvestigators.	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127714 UNITED STATES	11-Sep-03	94 IA Correspondence	Prot Amend	Add Subinvest	S:\CNS\FDA\Dvs-233 SR\IND\S089.doc Submission provides for a new investigator and the addition/deletion of subinvestigators.	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127847 UNITED STATES	16-Sep-03	95 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
128143 UNITED STATES	23-Sep-03	96 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
128391 UNITED STATES	29-Sep-03	97 IA Correspondence	Prot Amend	Add Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
128410 UNITED STATES	29-Sep-03	98 IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129413 UNITED STATES	24-Oct-03	99 IA Correspondence	Prot Amend	Add Invest		3151A1-308-WW	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

129556 UNITED STATES	28-Oct-03	100 IA Correspondence	Prot Amend	Add Invest				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129556 UNITED STATES	28-Oct-03	100 IA Correspondence	Prot Amend	Add Invest			3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129556 UNITED STATES	28-Oct-03	100 IA Correspondence	Prot Amend	Del Invest				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129556 UNITED STATES	28-Oct-03	100 IA Correspondence	Prot Amend	Del Invest			3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129560 UNITED STATES	28-Oct-03	101 IA Correspondence	Prot Amend	Add Invest				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129560 UNITED STATES	28-Oct-03	101 IA Correspondence	Prot Amend	Add Invest			3151A1-308-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129870 UNITED STATES	31-Oct-03	102 IA Correspondence	Info Amend-Clin	Address Change			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129870 UNITED STATES	31-Oct-03	102 IA Correspondence	Prot Amend	Add Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129870 UNITED STATES	31-Oct-03	102 IA Correspondence	Prot Amend	Del Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129870 UNITED STATES	31-Oct-03	102 IA Correspondence	Info Amend-Clin	Name Change			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
130393 UNITED STATES	14-Nov-03	103 IA Correspondence	CMC Issues	Other	Wyeth Meeting Minutes of 11-6-03 FDA/Wyeth			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
130393 UNITED STATES	14-Nov-03	103 IA Correspondence	Meeting/Telecon	Minutes	Wyeth Meeting Minutes of 11-6-03 FDA/Wyeth			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
130926 UNITED STATES	25-Nov-03	104 IA Correspondence	Clinical Issues	Info Request-Respon	Response to Reproductive-Related Comments			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131177 UNITED STATES	3-Dec-03	105 IA Correspondence	Prot Amend	Add Invest			3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131177 UNITED STATES	3-Dec-03	105 IA Correspondence	Prot Amend	Add Subinvest			3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131177 UNITED STATES	3-Dec-03	105 IA Correspondence	Prot Amend	Del Subinvest			3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131185 UNITED STATES	3-Dec-03	106 IA Correspondence	Prot Amend	Del Invest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131185 UNITED STATES	3-Dec-03	106 IA Correspondence	Prot Amend	Del Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131185 UNITED STATES	3-Dec-03	106 IA Correspondence	Prot Amend	Add Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131850 UNITED STATES	15-Dec-03	107 IA Correspondence	Response to	Review/Comment Req				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

131990 UNITED STATES	22-Dec-03	108 IA Correspondence	Prot Amend	New Protocol			3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131990 UNITED STATES	22-Dec-03	108 IA Correspondence	Prot Amend	Add Invest				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
131990 UNITED STATES	22-Dec-03	108 IA Correspondence	Prot Amend	Add Invest			3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
132614 UNITED STATES	15-Jan-04	109 IA Correspondence	Info Amend-CMC		IVIVC/Comparator Info			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
132848 UNITED STATES	15-Jan-04	110 IA Correspondence	Prot Amend	New Protocol			3151A1-177-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
133048 UNITED STATES	21-Jan-04	111 IA Correspondence	Prot Amend	New Protocol			3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
133064 UNITED STATES	21-Jan-04	112 IA Correspondence	Prot Amend	Add Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
133245 UNITED STATES	27-Jan-04	113 IA Correspondence	Gen Corr		Fulfillment of Pre-Phase 3 Meeting Request (Hypertension and Tachycardia)			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135809 UNITED STATES	31-Mar-04	113 IA Correspondence	Response to	Information Request	FDA will not need any more detailed information	######		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
133539 UNITED STATES	4-Feb-04	114 IA Correspondence	Safety Rpt: Clin	Initial Written	3151A1-303			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
133974 UNITED STATES	13-Feb-04	115 IA Correspondence	Request	Expedited Review	Request for Feedback on Mouse Carc Study Dose Adjustment			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134155 UNITED STATES	18-Feb-04	116 IA Correspondence	Safety Rpt: Clin	Follow-up	3151A1-303			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134201 UNITED STATES	19-Feb-04	117 IA Correspondence	Prot Amend	Add Subinvest			3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134201 UNITED STATES	19-Feb-04	117 IA Correspondence	Prot Amend	Del Subinvest			3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134247 UNITED STATES	20-Feb-04	118 IA Correspondence	Prot Amend	Add Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134247 UNITED STATES	20-Feb-04	118 IA Correspondence	Prot Amend	Del Subinvest			3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134356 UNITED STATES	23-Feb-04	119 IA Correspondence	Safety Rpt: Clin	Follow-up	3151A1-303			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134815 UNITED STATES	3-Mar-04	121 IA Correspondence	Prot Amend	Add Invest			3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134815 UNITED STATES	3-Mar-04	121 IA Correspondence	Prot Amend	Add Subinvest			3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134815 UNITED STATES	3-Mar-04	121 IA Correspondence	Prot Amend	Del Subinvest			3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

135628 UNITED STATES	22-Mar-04	122 IA Correspondence	Prot Amend	New Protocol		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135568 UNITED STATES	24-Mar-04	123 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135568 UNITED STATES	24-Mar-04	123 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135568 UNITED STATES	24-Mar-04	123 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135686 UNITED STATES	30-Mar-04	124 IA Correspondence	Prot Amend	Add Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135686 UNITED STATES	30-Mar-04	124 IA Correspondence	Prot Amend	Other		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135686 UNITED STATES	30-Mar-04	124 IA Correspondence	Prot Amend	Del Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135722 UNITED STATES	31-Mar-04	125 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135722 UNITED STATES	31-Mar-04	125 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135725 UNITED STATES	31-Mar-04	126 IA Correspondence	Info Amend-Clin	Address Change		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135725 UNITED STATES	31-Mar-04	126 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135725 UNITED STATES	31-Mar-04	126 IA Correspondence	Prot Amend	Other		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135727 UNITED STATES	31-Mar-04	127 IA Correspondence	Prot Amend	Change in Prot		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135919 UNITED STATES	7-Apr-04	128 IA Correspondence	Prot Amend	Add Invest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136035 UNITED STATES	8-Apr-04	129 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136084 UNITED STATES	9-Apr-04	130 IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136122 UNITED STATES	12-Apr-04	131 IA Correspondence	Safety Rpt: Clin	Follow-up	3151A1-303		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136478 UNITED STATES	21-Apr-04	132 IA Correspondence	Annual Report-IDA	Subm			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136516 UNITED STATES	22-Apr-04	133 IA Correspondence	Prot Amend	Add Invest		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136702 UNITED STATES	27-Apr-04	134 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

136800 UNITED STATES	30-Apr-04	135 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
136800 UNITED STATES	30-Apr-04	135 IA Correspondence	Prot Amend	Other		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
136800 UNITED STATES	30-Apr-04	135 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
136800 UNITED STATES	30-Apr-04	135 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137193 UNITED STATES	10-May-04	136 IA Correspondence	Info Amend-CMC		RPT Update		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137370 UNITED STATES	13-May-04	137 IA Correspondence	Prot Amend	Add Subinvest	Addition of a subinvestigator	3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137372 UNITED STATES	13-May-04	138 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137372 UNITED STATES	13-May-04	138 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137382 UNITED STATES	14-May-04	139 IA Correspondence	Prot Amend	Add Invest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137382 UNITED STATES	14-May-04	139 IA Correspondence	Prot Amend	Del Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137382 UNITED STATES	14-May-04	139 IA Correspondence	Prot Amend	Add Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137467 UNITED STATES	18-May-04	140 IA Correspondence	Prot Amend	New Protocol		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137467 UNITED STATES	18-May-04	140 IA Correspondence	Prot Amend	Add Invest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137475 UNITED STATES	18-May-04	141 IA Correspondence	Prot Amend	Add Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137475 UNITED STATES	18-May-04	141 IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137842 UNITED STATES	26-May-04	142 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137959 UNITED STATES	28-May-04	143 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137939 UNITED STATES	28-May-04	144 IA Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
137939 UNITED STATES	28-May-04	144 IA Correspondence	Protocol-Clinical	Other			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138060 UNITED STATES	2-Jun-04	144 IA Correspondence	Protocol-Clinical	Other	Copy of submission sent on 5/28 (S/N 144).		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

137998 UNITED STATES	2-Jun-04	145 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138020 UNITED STATES	2-Jun-04	146 IA Correspondence	Non-Clinical Issues	Info Req-Response	9 month Toxicity Study in Dogs.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138068 UNITED STATES	3-Jun-04	147 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138080 UNITED STATES	3-Jun-04	148 IA Correspondence	Info Amend-Clin	Research Facil - Add		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138080 UNITED STATES	3-Jun-04	148 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138080 UNITED STATES	3-Jun-04	148 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138080 UNITED STATES	3-Jun-04	148 IA Correspondence	Info Amend-Clin	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138080 UNITED STATES	3-Jun-04	148 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138100 UNITED STATES	4-Jun-04	149 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138123 UNITED STATES	7-Jun-04	150 IA Correspondence	Prot Amend	Add Invest		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138421 UNITED STATES	14-Jun-04	151 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138421 UNITED STATES	14-Jun-04	151 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138423 UNITED STATES	14-Jun-04	152 IA Correspondence	Info Amend-Clin	Address Change		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138423 UNITED STATES	14-Jun-04	152 IA Correspondence	Prot Amend	Del Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138425 UNITED STATES	14-Jun-04	153 IA Correspondence	Prot Amend	Add Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138443 UNITED STATES	14-Jun-04	154 IA Correspondence	Prot Amend	New Protocol		3151A1-180-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138472 UNITED STATES	15-Jun-04	155 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138567 UNITED STATES	17-Jun-04	157 IA Correspondence	Request	Review/Comment	Request FDA feedback regarding the proposed specific analyses of the DESS data.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138578 UNITED STATES	17-Jun-04	158 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138601 UNITED STATES	18-Jun-04	159 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

138847 UNITED STATES	21-Jun-04	160 IA Correspondence	Prot Amend	Change in Prot		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138717 UNITED STATES	24-Jun-04	161 IA Correspondence	Prot Amend	New Protocol		3151A1-181-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138787 UNITED STATES	24-Jun-04	162 IA Correspondence	Prot Amend	Change in Prot		3151A1-308-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138866 UNITED STATES	28-Jun-04	163 IA Correspondence	Safety Rpt: Clin	Init Writ\Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138967 UNITED STATES	30-Jun-04	164 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138967 UNITED STATES	30-Jun-04	164 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138967 UNITED STATES	30-Jun-04	164 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
138969 UNITED STATES	30-Jun-04	165 IA Correspondence	Info Amend-CMC		Update to DP & DS, HPLC analytical method for DS purity, stability data for DP & DS		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139026 UNITED STATES	1-Jul-04	166 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139026 UNITED STATES	1-Jul-04	166 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139082 UNITED STATES	2-Jul-04	167 IA Correspondence	Info Amend-Clin	Address Change		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139082 UNITED STATES	2-Jul-04	167 IA Correspondence	Prot Amend	Add Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139082 UNITED STATES	2-Jul-04	167 IA Correspondence	Prot Amend	Del Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139527 UNITED STATES	20-Jul-04	168 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139569 UNITED STATES	21-Jul-04	169 IA Correspondence	Prot Amend	Change in Prot		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139569 UNITED STATES	21-Jul-04	169 IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139841 UNITED STATES	30-Jul-04	170 IA Correspondence	Prot Amend	Add Invest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139841 UNITED STATES	30-Jul-04	170 IA Correspondence	Prot Amend	Add Subinvest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139853 UNITED STATES	2-Aug-04	171 IA Correspondence	Prot Amend	Add Invest		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139890 UNITED STATES	2-Aug-04	172 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

139890 UNITED STATES	2-Aug-04	172 IA Correspondence	Prot Amend	Other		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
139890 UNITED STATES	2-Aug-04	172 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
139967 UNITED STATES	4-Aug-04	173 IA Correspondence	Prot Amend	Add Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
139969 UNITED STATES	4-Aug-04	174 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
139969 UNITED STATES	4-Aug-04	174 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
140265 UNITED STATES	10-Aug-04	175 IA Correspondence	Prot Amend	New Protocol	3151A1-307-US A 6-Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
140265 UNITED STATES	10-Aug-04	175 IA Correspondence	Prot Amend	New Protocol	3151A1-307-US A 6-Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
140847 UNITED STATES	20-Aug-04	176 IA Correspondence	Safety Rpt. Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141197 UNITED STATES	31-Aug-04	177 IA Correspondence	Prot Amend	Add Subinvest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141197 UNITED STATES	31-Aug-04	177 IA Correspondence	Prot Amend	Del Subinvest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141198 UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Add Invest		3151A1-308-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141198 UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141198 UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Del Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141198 UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141238 UNITED STATES	1-Sep-04	179 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141238 UNITED STATES	1-Sep-04	179 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141243 UNITED STATES	1-Sep-04	180 IA Correspondence	Info Amend-Clin	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141243 UNITED STATES	1-Sep-04	180 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
141243 UNITED STATES	1-Sep-04	180 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

141258 UNITED STATES	2-Sep-04	181 IA Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141258 UNITED STATES	2-Sep-04	181 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141278 UNITED STATES	2-Sep-04	182 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141330 UNITED STATES	3-Sep-04	183 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141390 UNITED STATES	9-Sep-04	184 IA Correspondence	Info Amend-Clin	Address Change	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141390 UNITED STATES	9-Sep-04	184 IA Correspondence	Prot Amend	Add Invest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141390 UNITED STATES	9-Sep-04	184 IA Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141390 UNITED STATES	9-Sep-04	184 IA Correspondence	Prot Amend	Add Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141390 UNITED STATES	9-Sep-04	184 IA Correspondence	Info Amend-Clin	Name Change	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141830 UNITED STATES	16-Sep-04	185 IA Correspondence	Prot Amend	Change in Prot	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141897 UNITED STATES	17-Sep-04	186 IA Correspondence	Prot Amend	Add Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141897 UNITED STATES	17-Sep-04	186 IA Correspondence	Prot Amend	Add Subinvest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142116 UNITED STATES	22-Sep-04	187 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142334 UNITED STATES	27-Sep-04	188 IA Correspondence	Prot Amend	Add Invest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add IRB	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Research Facil	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

142509 UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142570 UNITED STATES	30-Sep-04	190 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Add Invest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Add IRB	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Add Research Facil	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Del Subinvest	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Add Subinvest	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142906 UNITED STATES	6-Oct-04	191 IA Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143140 UNITED STATES	12-Oct-04	192 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143433 UNITED STATES	18-Oct-04	193 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Add Invest	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Add Subinvest	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Add Research Facil	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Add IRB	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143543 UNITED STATES	20-Oct-04	194 IA Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

143573 UNITED STATES	20-Oct-04	195 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144040 UNITED STATES	29-Oct-04	196 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144241 UNITED STATES	10-Nov-04	197 IA Correspondence	Meeting/Telecon	Meeting-Request	Type A meeting request for 150 mg		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144253 UNITED STATES	2-Nov-04	198 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144652 UNITED STATES	9-Nov-04	199 IA Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144722 UNITED STATES	10-Nov-04	200 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144739 UNITED STATES	10-Nov-04	201 IA Correspondence	Prot Amend	Change in Prot			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144848 UNITED STATES	11-Nov-04	202 IA Correspondence	Info Amend-CMC		CMC information to support manufacturing equipment change; Avelox as a positive control		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
144948 UNITED STATES	15-Nov-04	203 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Invest		3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Del Subinvest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Name Change		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add IRB		3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add IRB		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Research Facil		3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Research Facil	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Address Change	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145272 UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145274 UNITED STATES	19-Nov-04	205 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145325 UNITED STATES	22-Nov-04	206 IA Correspondence	Safety Rpt: Clin	Init Writ\Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145346 UNITED STATES	22-Nov-04	207 IA Correspondence	Info Amend-Pharm/Tox			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145426 UNITED STATES	23-Nov-04	208 IA Correspondence	Response to	Information Request		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
145713 UNITED STATES	1-Dec-04	209 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146010 UNITED STATES	6-Dec-04	210 IA Correspondence	Safety Rpt: Clin	Init Writ\Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146888 UNITED STATES	20-Dec-04	211 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Add Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Add IRB	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Add Research Facil	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Name Change	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Add Subinvest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

146924 UNITED STATES	20-Dec-04	212 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147028 UNITED STATES	22-Dec-04	213 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147168 UNITED STATES	23-Dec-04	214 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147291 UNITED STATES	29-Dec-04	215 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147707 UNITED STATES	7-Jan-05	216 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147707 UNITED STATES	7-Jan-05	216 IA Correspondence	Prot Amend	New Protocol	3151A1-193-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147797 UNITED STATES	11-Jan-05	217 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147797 UNITED STATES	11-Jan-05	217 IA Correspondence	Prot Amend	New Protocol	3151A1-183-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147844 UNITED STATES	11-Jan-05	218 IA Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148017 UNITED STATES	14-Jan-05	219 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148017 UNITED STATES	14-Jan-05	219 IA Correspondence	Prot Amend	New Protocol	3151A1-194-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148104 UNITED STATES	17-Jan-05	220 IA Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148217 UNITED STATES	19-Jan-05	221 IA Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add Invest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Name Change	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Name Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Name Change	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Address Change	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Address Change	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Del Subinvest	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add IRB	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148262 UNITED STATES	19-Jan-05	222 IA Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148302 UNITED STATES	20-Jan-05	223 IA Correspondence	Request	Other		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148413 UNITED STATES	24-Jan-05	224 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148696 UNITED STATES	28-Jan-05	225 IA Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148901 UNITED STATES	1-Feb-05	226 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
148901 UNITED STATES	1-Feb-05	226 IA Correspondence	Prot Amend	New Protocol	3151A1-195-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149144 UNITED STATES	7-Feb-05	227 IA Correspondence	Safety Rpt: Clin	Init Writ\Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149388 UNITED STATES	10-Feb-05	228 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149440 UNITED STATES	11-Feb-05	229 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149611 UNITED STATES	15-Feb-05	230 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Del Invest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Subinvest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add IRB	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Research Facil	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Address Change	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Del Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Del Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149809 UNITED STATES	18-Feb-05	231 IA Correspondence	Prot Amend	Add Invest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
149837 UNITED STATES	22-Feb-05	232 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
150058 UNITED STATES	23-Feb-05	233 IA Correspondence	Safety Rpt: Clin	7-Day P/F & Initial		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

150187 UNITED STATES	23-Feb-05	233 IA Correspondence	Safety Rpt: Clin	7-Day P/F & Initial			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
150191 UNITED STATES	24-Feb-05	234 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
150327 UNITED STATES	25-Feb-05	235 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
150529 UNITED STATES	2-Mar-05	236 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
150555 UNITED STATES	3-Mar-05	237 IA Correspondence	Info Amend-CMC		FDA email correspondence regarding biowaiver		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151031 UNITED STATES	10-Mar-05	238 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151509 UNITED STATES	18-Mar-05	239 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Address Change		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Name Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add Research Facil		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add Subinvest		0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add IRB		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add Research Facil		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Add Research Facil		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Name Change		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Address Change	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Address Change	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151514 UNITED STATES	18-Mar-05	240 IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151525 UNITED STATES	18-Mar-05	241 IA Correspondence	Prot Amend	Change in Prot	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151553 UNITED STATES	21-Mar-05	242 IA Correspondence	Request	Review/Comment		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151588 UNITED STATES	21-Mar-05	243 IA Correspondence	Info Amend-Pharm/Tox			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151742 UNITED STATES	23-Mar-05	244 IA Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
152472 UNITED STATES	5-Apr-05	245 IA Correspondence	Info Amend-Pharm/Tox			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
152473 UNITED STATES	5-Apr-05	246 IA Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
152541 UNITED STATES	6-Apr-05	247 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153078 UNITED STATES	14-Apr-05	248 IA Correspondence	Response to	Information Request		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153137 UNITED STATES	15-Apr-05	249 IA Correspondence	Safety Rpt Clin	Init Writ\Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240 UNITED STATES	18-Apr-05	250 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240 UNITED STATES	18-Apr-05	250 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240 UNITED STATES	18-Apr-05	250 IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240 UNITED STATES	18-Apr-05	250 IA Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240 UNITED STATES	18-Apr-05	250 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240 UNITED STATES	18-Apr-05	250 IA Correspondence	Prot Amend	Add Subinvest	3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153536 UNITED STATES	21-Apr-05	251 IA Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
154192 UNITED STATES	2-May-05	252 IA Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

154200 UNITED STATES	2-May-05	253 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
154283 UNITED STATES	3-May-05	254 IA Correspondence	Info Amend-Pharm/Tox			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
154683 UNITED STATES	10-May-05	255 IA Correspondence	Safety Rpt: Clin	Init Writt\Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
154825 UNITED STATES	12-May-05	256 IA Correspondence	Prot Amend	Change in Prot	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
154843 UNITED STATES	12-May-05	257 IA Correspondence	Prot Amend	Change in Prot	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
154976 UNITED STATES	16-May-05	258 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del Subinvest	0600D3-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del IRB	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Del IRB	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add IRB	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add IRB	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Name Change		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add Subinvest		0600D3-223-PL	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155092 UNITED STATES	18-May-05	259 IA Correspondence	Prot Amend	Add Subinvest		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155180 UNITED STATES	19-May-05	260 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156114 UNITED STATES	27-May-05	261 IA Correspondence	Meeting/Telecon	Info	Meeting/Telecon 15-JUN-05.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156379 UNITED STATES	9-Jun-05	262 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156384 UNITED STATES	9-Jun-05	263 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156783 UNITED STATES	15-Jun-05	264 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Invest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Research Facil		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Address Change		3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Subinvest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Subinvest		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Subinvest		3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Del Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest	3151A1-307-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
156892 UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
157290 UNITED STATES	24-Jun-05	266 IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
157290 UNITED STATES	24-Jun-05	266 IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
157290 UNITED STATES	24-Jun-05	266 IA Correspondence	Prot Amend	Name Change	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
157516 UNITED STATES	28-Jun-05	267 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158521 UNITED STATES	14-Jul-05	268 IA Correspondence	Meeting/Telecon	Backgrnd Pkg-Request		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Invest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Add Subinvest	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
158610 UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Add Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
159351 UNITED STATES	27-Jul-05	270 IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
159351 UNITED STATES	27-Jul-05	270 IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
159648 UNITED STATES	2-Aug-05	271 IA Correspondence	Prot Amend	Change in Prot	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
159661 UNITED STATES	2-Aug-05	272 IA Correspondence	Prot Amend	Change in Prot	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

159712 UNITED STATES	3-Aug-05	273 IA Correspondence	Other		Protocol 309-EU statistical analysis plan		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
159713 UNITED STATES	4-Aug-05	274 IA Correspondence	Prot Amend	Change in Prot		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160176 UNITED STATES	11-Aug-05	275 IA Correspondence	Safety Rpt. Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		3151A1-308-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160411 UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Address Change		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161659 UNITED STATES	14-Sep-05	277 IA Correspondence	Annual Report-IDA	Subm			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Del Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Address Change		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add IRB		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Research Facil		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161797 UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162277 UNITED STATES	27-Sep-05	279 IA Correspondence	Meeting/Telecon	Minutes	pre-NDA meeting minutes		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162589 UNITED STATES	3-Oct-05	280 IA Correspondence	Response to	Information Request	Response to FDA Request - Ven Mass Balance study		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162968 UNITED STATES	7-Oct-05	281 IA Correspondence	Info Amend-CMC		Pre NDA-CMC meeting request/package		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Add Invest		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Address Change		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Add IRB		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Add Research Facil		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Add Subinvest		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163351 UNITED STATES	13-Oct-05	282 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163392 UNITED STATES	14-Oct-05	283 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
164361 UNITED STATES	2-Nov-05	284 IA Correspondence	Meeting/Telecon	Minutes	Pre-NDA CMC Type C Meeting.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
164910 UNITED STATES	11-Nov-05	285 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
164910 UNITED STATES	11-Nov-05	285 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
164910 UNITED STATES	11-Nov-05	285 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
166430 UNITED STATES	6-Dec-05	286 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
166430 UNITED STATES	8-Dec-05	286 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
166594 UNITED STATES	13-Dec-05	287 IA Correspondence	Info Amend-CMC		Updated DS specs & DP manufactured using roller compaction		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

167468 UNITED STATES	4-Jan-06	288 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
167468 UNITED STATES	4-Jan-06	288 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
167691 UNITED STATES	11-Jan-06	289 IA Correspondence	Response to	Information Request	Status of Reproductive Fertility Studies		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
168172 UNITED STATES	24-Jan-06	290 IA Correspondence	Prot Amend	New Protocol		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
168852 UNITED STATES	3-Feb-06	291 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
169563 UNITED STATES	21-Feb-06	292 IA Correspondence	Prot Amend	New Protocol		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
170271 UNITED STATES	2-Mar-06	293 IA Correspondence	Prot Amend	Change in Prot		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
170331 UNITED STATES	3-Mar-06	294 IA Correspondence	Prot Amend	Add Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
170331 UNITED STATES	3-Mar-06	294 IA Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
170657 UNITED STATES	6-Mar-06	295 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
171052 UNITED STATES	15-Mar-06	296 IA Correspondence	Prot Amend	New Protocol		3151A1-900-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
171265 UNITED STATES	16-Mar-06	297 IA Correspondence	Prot Amend	New Protocol		3151A1-198-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
172348 UNITED STATES	30-Mar-06	298 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
172348 UNITED STATES	30-Mar-06	298 IA Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
172348 UNITED STATES	30-Mar-06	298 IA Correspondence	Prot Amend	Add Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
172348 UNITED STATES	30-Mar-06	298 IA Correspondence	Prot Amend	Del Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
172348 UNITED STATES	30-Mar-06	298 IA Correspondence	Prot Amend	Add Subinvest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
173044 UNITED STATES	12-Apr-06	299 IA Correspondence	Annual Report-IDA	Subm			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
173324 UNITED STATES	18-Apr-06	300 IA Correspondence	Prot Amend	New Protocol		3151A1-901-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
173883 UNITED STATES	24-Apr-06	301 IA Correspondence	Request	Review/Comment	9-week Juvenile Rat Toxicity Study		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

173914 UNITED STATES	26-Apr-06	302 IA Correspondence	Prot Amend	Change in Prot	Change in Protocol Amendment 1 for 3151A1-332-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
173997 UNITED STATES	27-Apr-06	303 IA Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
174912 UNITED STATES	11-May-06	304 IA Correspondence	Safety Rpt. Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175646 UNITED STATES	24-May-06	305 IA Correspondence	Prot Amend	Change in Prot		3151A1-900-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175805 UNITED STATES	25-May-06	306 IA Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175805 UNITED STATES	25-May-06	306 IA Correspondence	Prot Amend	Add IRB		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175805 UNITED STATES	25-May-06	306 IA Correspondence	Prot Amend	Add Research Facil		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175805 UNITED STATES	25-May-06	306 IA Correspondence	Prot Amend	Add Subinvest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176530 UNITED STATES	7-Jun-06	307 IA Correspondence	Prot Amend	Change in Prot		3151A1-901-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176569 UNITED STATES	8-Jun-06	308 IA Correspondence	Prot Amend	Change in Prot			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176569 UNITED STATES	8-Jun-06	308 IA Correspondence	Prot Amend	Change in Prot		3151A1-900-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176551 UNITED STATES	7-Jul-06	309 IA Correspondence	Prot Amend	Add Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176551 UNITED STATES	7-Jul-06	309 IA Correspondence	Prot Amend	Add Subinvest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176551 UNITED STATES	7-Jul-06	309 IA Correspondence	Prot Amend	Del Subinvest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176551 UNITED STATES	7-Jul-06	309 IA Correspondence	Prot Amend	Del Subinvest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176551 UNITED STATES	7-Jul-06	309 IA Correspondence	Prot Amend	Add Subinvest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176666 UNITED STATES	11-Jul-06	310 IA Correspondence	Other		Submission of SAP for Study 303 (MDD)		FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
176783 UNITED STATES	13-Jul-06	311 IA Correspondence	Response to	Review/Comment Req	Statistical criteria for Amendemnt 3		FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
179350 UNITED STATES	21-Jul-06	312 IA Correspondence	Prot Amend	Add Research Facil		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
179350 UNITED STATES	21-Jul-06	312 IA Correspondence	Prot Amend	Add IRB		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

179350 UNITED STATES	21-Jul-06	312 IA Correspondence	Prot Amend	Add Invest	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
180655 UNITED STATES	9-Aug-06	313 IA Correspondence	Prot Amend	New Protocol	3151A1-401-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del Invest	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del IRB	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del IRB	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add IRB	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add IRB	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add IRB	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Research Facil	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Research Facil	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Research Facil	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Address Change	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del IRB	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Address Change	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del Subinvest	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del Subinvest	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Subinvest	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Subinvest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Del Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 IA Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
194373 UNITED STATES	8-Sep-06	315 IA Correspondence	Prot Amend	New Protocol		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183133 UNITED STATES	15-Sep-06	316 IA Correspondence	Info Amend-CMC		Submission of duloxetine and a corresponding placebo as a comparator		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183475 UNITED STATES	21-Sep-06	317 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183515 UNITED STATES	22-Sep-06	318 IA Correspondence	Prot Amend	New Protocol		3151A1-335-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183784 UNITED STATES	27-Sep-06	319 IA Correspondence	Prot Amend	Change in Prot		3151A1-900-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183851 UNITED STATES	27-Sep-06	320 IA Correspondence	Prot Amend	Change in Prot		3151A1-332-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183931 UNITED STATES	28-Sep-06	321 IA Correspondence	Prot Amend	Change in Prot		3151A1-401-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
185019 UNITED STATES	13-Oct-06	322 IA Correspondence	Prot Amend	Investigator Data		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
185019 UNITED STATES	13-Oct-06	322 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
185019 UNITED STATES	13-Oct-06	322 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
185019 UNITED STATES	13-Oct-06	322 IA Correspondence	Prot Amend	Investigator Data		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
185817 UNITED STATES	24-Oct-06	323 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
185962 UNITED STATES	25-Oct-06	324 IA Correspondence	Info Amend-CMC		Submission of comparator Lexapro		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
186700 UNITED STATES	3-Nov-06	325 IA Correspondence	Prot Amend	New Protocol		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

187070 UNITED STATES	9-Nov-06	326 IA Correspondence	Prot Amend	Investigator Data	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
187070 UNITED STATES	9-Nov-06	326 IA Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
188007 UNITED STATES	22-Nov-06	327 IA Correspondence	Prot Amend	Change in Prot	3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
188007 UNITED STATES	22-Nov-06	327 IA Correspondence	Request	Concurrence		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
188018 UNITED STATES	22-Nov-06	328 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
188147 UNITED STATES	27-Nov-06	329 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189690 UNITED STATES	15-Dec-06	330 IA Correspondence	Prot Amend	Investigator Data	3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189690 UNITED STATES	15-Dec-06	330 IA Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189891 UNITED STATES	19-Dec-06	331 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189965 UNITED STATES	20-Dec-06	332 IA Correspondence	Prot Amend	New Protocol	3151A1-1203-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189971 UNITED STATES	20-Dec-06	333 IA Correspondence	Prot Amend	Investigator Data	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189971 UNITED STATES	20-Dec-06	333 IA Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189971 UNITED STATES	20-Dec-06	333 IA Correspondence	Prot Amend	Investigator Data	3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189971 UNITED STATES	20-Dec-06	333 IA Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189971 UNITED STATES	20-Dec-06	333 IA Correspondence	Prot Amend	Investigator Data	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
189995 UNITED STATES	21-Dec-06	334 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
190058 UNITED STATES	22-Dec-06	335 IA Correspondence	Safety Rpt: Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
190984 UNITED STATES	15-Jan-07	336 IA Correspondence	Prot Amend	Investigator Data	3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
190984 UNITED STATES	15-Jan-07	338 IA Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
192403 UNITED STATES	6-Feb-07	337 IA Correspondence	Safety Rpt: Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

192586 UNITED STATES	8-Feb-07	338 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
192761 UNITED STATES	9-Feb-07	339 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
192850 UNITED STATES	12-Feb-07	340 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
192927 UNITED STATES	14-Feb-07	341 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193158 UNITED STATES	16-Feb-07	342 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193343 UNITED STATES	20-Feb-07	343 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193928 UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193928 UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193928 UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193928 UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
193928 UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194271 UNITED STATES	7-Mar-07	345 IA Correspondence	Prot Amend	Change in Prot		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194562 UNITED STATES	12-Mar-07	346 IA Correspondence	Prot Amend	Change in Prot		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194562 UNITED STATES	12-Mar-07	346 IA Correspondence	Prot Amend	Change in Prot		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194565 UNITED STATES	13-Mar-07	347 IA Correspondence	Info Amend-CMC		Information on the blinded comparator Paroxetine.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194745 UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194745 UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194745 UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
194745 UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
196088 UNITED STATES	2-Apr-07	349 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

196668 UNITED STATES	6-Apr-07	350 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
196668 UNITED STATES	6-Apr-07	350 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
196668 UNITED STATES	6-Apr-07	350 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
196865 UNITED STATES	10-Apr-07	351 IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
197389 UNITED STATES	16-Apr-07	352 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
198111 UNITED STATES	26-Apr-07	353 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
199156 UNITED STATES	8-May-07	354 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
199156 UNITED STATES	8-May-07	354 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
199156 UNITED STATES	8-May-07	354 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
199838 UNITED STATES	17-May-07	355 IA Correspondence	Prot Amend	New Protocol	New Protocol and SAP	3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
199897 UNITED STATES	17-May-07	356 IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
200655 UNITED STATES	25-May-07	357 IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
201023 UNITED STATES	31-May-07	358 IA Correspondence	Annual Report-IDA	Subm	IND Annual Report		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
201503 UNITED STATES	6-Jun-07	359 IA Correspondence	Prot Amend	Investigator Data		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
201503 UNITED STATES	6-Jun-07	359 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
201503 UNITED STATES	6-Jun-07	359 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
201918 UNITED STATES	12-Jun-07	360 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
202107 UNITED STATES	14-Jun-07	361 IA Correspondence	Prot Amend	Change in Prot		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
202581 UNITED STATES	20-Jun-07	362 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
203066 UNITED STATES	27-Jun-07	363 IA Correspondence	Prot Amend	Investigator Data		3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

203068 UNITED STATES	27-Jun-07	363 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
205338 UNITED STATES	26-Jul-07	364 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
205338 UNITED STATES	26-Jul-07	364 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
205338 UNITED STATES	26-Jul-07	364 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
205840 UNITED STATES	1-Aug-07	365 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
206045 UNITED STATES	2-Aug-07	366 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
207165 UNITED STATES	17-Aug-07	367 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
207661 UNITED STATES	23-Aug-07	368 IA Correspondence	Prot Amend	Investigator Data		3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
207661 UNITED STATES	23-Aug-07	368 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
208295 UNITED STATES	31-Aug-07	369 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
209223 UNITED STATES	17-Sep-07	370 IA Correspondence	Prot Amend	Change in Prot		3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
209949 UNITED STATES	19-Sep-07	371 IA Correspondence	Prot Amend	Add Invest		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
209949 UNITED STATES	19-Sep-07	371 IA Correspondence	Prot Amend	Add Invest		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
209949 UNITED STATES	19-Sep-07	371 IA Correspondence	Prot Amend	Add Invest		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
211301 UNITED STATES	2-Oct-07	372 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
212015 UNITED STATES	10-Oct-07	373 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
212919 UNITED STATES	17-Oct-07	374 IA Correspondence	Other		Final Statistical Analysis Plan for Study 335-US		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
213039 UNITED STATES	18-Oct-07	375 IA Correspondence	Prot Amend	Investigator Data		3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
213039 UNITED STATES	18-Oct-07	375 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
213039 UNITED STATES	18-Oct-07	375 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

213396 UNITED STATES	23-Oct-07	376 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
213647 UNITED STATES	25-Oct-07	377 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
215529 UNITED STATES	15-Nov-07	378 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
216773 UNITED STATES	6-Dec-07	379 IA Correspondence	Info Amend-CMC		To submit 10/25 mg CMC information		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
217794 UNITED STATES	10-Dec-07	380 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218016 UNITED STATES	11-Dec-07	381 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218614 UNITED STATES	17-Dec-07	382 IA Correspondence	Prot Amend	Change in Prot		3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218615 UNITED STATES	17-Dec-07	383 IA Correspondence	Safety Rpt: Clin	7-Day P/F & Initial			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218710 UNITED STATES	17-Dec-07	383 IA Correspondence	Safety Rpt: Clin	7-Day P/F & Initial			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218897 UNITED STATES	18-Dec-07	384 IA Correspondence	Other		Pediatric Study Request		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218721 UNITED STATES	19-Dec-07	385 IA Correspondence	Prot Amend	New Protocol		3151A6-2000-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
218777 UNITED STATES	19-Dec-07	386 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
219306 UNITED STATES	19-Dec-07	386 IA Correspondence	Safety Rpt: Clin	7-Day P/F & Initial			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
219057 UNITED STATES	20-Dec-07	387 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
219255 UNITED STATES	2-Jan-08	388 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
219304 UNITED STATES	3-Jan-08	389 IA Correspondence	Prot Amend	New Protocol		3151A6-2001-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
220802 UNITED STATES	15-Jan-08	390 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
220802 UNITED STATES	15-Jan-08	390 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
221239 UNITED STATES	16-Jan-08	391 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
221260 UNITED STATES	17-Jan-08	392 IA Correspondence	Prot Amend	Investigator Data		3151A6-2000-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

223906 UNITED STATES	15-Feb-08	393 IA Correspondence	Prot Amend	Investigator Data		3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
223906 UNITED STATES	15-Feb-08	393 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
223906 UNITED STATES	15-Feb-08	393 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
223906 UNITED STATES	15-Feb-08	393 IA Correspondence	Prot Amend	Investigator Data		3151A6-2000-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225077 UNITED STATES	29-Feb-08	394 IA Correspondence	Safety Rpt: Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225601 UNITED STATES	11-Mar-08	395 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225861 UNITED STATES	14-Mar-08	396 IA Correspondence	Prot Amend	Investigator Data		3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225861 UNITED STATES	14-Mar-08	396 IA Correspondence	Prot Amend	Investigator Data		3151A6-2001-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225861 UNITED STATES	14-Mar-08	396 IA Correspondence	Prot Amend	Investigator Data		3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225861 UNITED STATES	14-Mar-08	396 IA Correspondence	Prot Amend	Investigator Data		3151A6-2000-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
225861 UNITED STATES	14-Mar-08	396 IA Correspondence	Prot Amend	Investigator Data		3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
226429 UNITED STATES	20-Mar-08	397 IA Correspondence	Prot Amend	Change in Prot		3151A6-2001-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
226523 UNITED STATES	21-Mar-08	398 IA Correspondence	Safety Rpt: Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105188 UNITED STATES	22-Apr-02	IA Correspondence	Request	Info			Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105187 UNITED STATES	19-Apr-02	IA Correspondence	Initial IDA	Other	Additional Desk Copies of IND - Cover Memo Only		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105190 UNITED STATES	18-Apr-02	IA Correspondence	Initial IDA	Other	Additional Copy of Initial IND		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105633 UNITED STATES	2-May-02	IA Correspondence	CMC Issues	Info Request-Respon			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129575 UNITED STATES	24-Oct-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129561 UNITED STATES	23-Oct-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
129560 UNITED STATES	24-Oct-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

126162 UNITED STATES	14-Mar-03	IA Correspondence	Request	Info		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127320 UNITED STATES	25-Aug-03	IA Correspondence	Request	Info		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127319 UNITED STATES	2-Sep-03	IA Correspondence	Response to	Information Request		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
127235 UNITED STATES	7-Aug-03	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126119 UNITED STATES	14-Feb-03	IA Correspondence	Request	Review/Comment		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126107 UNITED STATES	31-Jul-03	IA Correspondence	Response to	Review/Comment Req		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
126020 UNITED STATES	28-Feb-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125987 UNITED STATES	4-Feb-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
113475 UNITED STATES	30-Oct-02	IA Correspondence	Protocol-Clinical	Other	FDA Commendations re New Prot Submission, 0600D3-172-US	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
112688 UNITED STATES	30-Sep-02	IA Correspondence	Clinical Issues	Other	Clinical Trials Data Bank Info		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
112590 UNITED STATES	6-May-02	IA Correspondence	Protocol-Clinical	Information-Request	re: 0600D3-170-EU study	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
112587 UNITED STATES	6-May-02	IA Correspondence	CMC Issues	Information-Request		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
108455 UNITED STATES	6-May-02	IA Correspondence	CMC Issues	Info Request-Respon		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
181420 UNITED STATES	20-May-05	IA-GRR Note to File	Other		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
179393 UNITED STATES	20-Jul-06	IA Correspondence	Non-Clinical Issues	Other	Advice on dose selection.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
178414 UNITED STATES	26-Jun-06	IA Correspondence	Prot Amend	New Protocol	Agency finds protocol #3151A1-900-US acceptable.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
178705 UNITED STATES	9-Jun-06	IA Correspondence	Gen Corr		Miscellaneous issues.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
175428 UNITED STATES	27-Oct-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
175419 UNITED STATES	27-Oct-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
175379 UNITED STATES	8-Sep-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

175371 UNITED STATES	20-Sep-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175237 UNITED STATES	15-Jun-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175234 UNITED STATES	15-Jun-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
173593 UNITED STATES	20-Apr-06	IA Correspondence	Response to	Review/Comment Req	S/N 293 Review.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168476 UNITED STATES	27-Jan-06	IA Correspondence	Response to	Information Request	Answer to question on the Toxicology Amendment.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168123 UNITED STATES	23-Jan-06	IA Correspondence	Gen Corr		Interpretation of e-mail on Toxicology amendment.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168122 UNITED STATES	23-Jan-06	IA Correspondence	Response to	Information Request	Toxicology amendment.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168113 UNITED STATES	20-Jan-06	IA Correspondence	Request	Info	Question on toxicology reports.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
167618 UNITED STATES	26-Aug-05	IA Correspondence	Gen Corr		Acknowledged receipt of e-mail dated 18-AUG-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
167519 UNITED STATES	19-Dec-05	IA Correspondence	Meeting/Telecon	Info	Include conversation with Dr. Oliver regarding the stability data.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
167517 UNITED STATES	8-Dec-05	IA Correspondence	Meeting/Telecon	Minutes	27-OCT-2005 Teleconference.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
166938 UNITED STATES	25-Nov-05	IA Correspondence	Meeting/Telecon	Minutes	Discuss Pre-NDA CMC issues.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165927 UNITED STATES	23-Nov-05	IA Correspondence	CMC Issues	Other	Stability Data.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165804 UNITED STATES	28-Nov-05	IA Correspondence	Gen Corr		Acknowledged receipt of e-mail dated 28-NOV-2005 - statistical comments.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165803 UNITED STATES	28-Nov-05	IA Correspondence	Gen Corr		Resending message dated 25-NOV-2005 - statistical ccomments.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165801 UNITED STATES	23-Nov-05	IDA-FDA Con Rpt	Phone	General	To obtain concurrence from the Agency.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164750 UNITED STATES	28-Apr-03	IA Correspondence	Meeting/Telecon	Minutes	Minutes and overheads of 4-10-03.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164425 UNITED STATES	19-Oct-05	IA Correspondence	Meeting/Telecon	Confirm	Type C meeting to be held 27-OCT-2005.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164201 UNITED STATES	21-Oct-05	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues	Teleconference scheduled for 27-OCT-2005.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164201 UNITED STATES	21-Oct-05	IDA-FDA Con Rpt	Phone	CMC Issues	Teleconference scheduled for 27-OCT-2005.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

164171 UNITED STATES	21-Oct-05	IA Correspondence	CMC Issues	Other	There will be no additional question to include to the meeting package.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163801 UNITED STATES	20-Oct-05	IA Correspondence	Gen Corr		eCTD interactive demonstration.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163770 UNITED STATES	19-Oct-05	IA Correspondence	Meeting/Telecon	Mtg Req-Response	Telecon granted 27-OCT-05.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163636 UNITED STATES	28-Sep-05	IA Correspondence	Meeting/Telecon	Minutes	Minutes and Presentation of 20-SEP-05 CMC Pilot Program.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163543 UNITED STATES	11-Oct-05	IA Correspondence	Meeting/Telecon	Info	Date correction - 27-OCT-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163542 UNITED STATES	10-Oct-05	IA Correspondence	Meeting/Telecon	Info	Tentatively scheduled 20-OCT-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163539 UNITED STATES	13-Oct-05	IA Correspondence	Meeting/Telecon	Info	Teleconference information for 27-OCT-2005.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163406 UNITED STATES	11-Oct-05	IDA-FDA Con Rpt	Phone	CMC Issues	Confirmed receipt of the CMC meeting request and information package.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
163034 UNITED STATES	5-Oct-05	IA Correspondence	Meeting/Telecon	Info	CMC meeting package scheduled 27-OCT-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162696 UNITED STATES	30-Sep-05	IA Correspondence	Meeting/Telecon	Minutes	Minutes of 8-SEP-05.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162487 UNITED STATES	29-Sep-05	IA Correspondence	Gen Corr		eCTD interactive demonstration.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162069 UNITED STATES	8-Sep-05	IA Correspondence	Meeting/Telecon	Confirm	Type C meeting scheduled for 20-SEP-05. Discuss CMC information.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
162039 UNITED STATES	20-Sep-05	IA Correspondence	Meeting/Telecon	Info	Detailed feedback requested of the meeting held 8-SEP-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161861 UNITED STATES	1-Sep-05	IA Correspondence	CMC Issues	Info Request-Respon	Accepted to the Pilot program.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161521 UNITED STATES	7-Sep-05	IA Correspondence	Meeting/Telecon	Info	Information regarding 8-SEP-05 meeting.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161513 UNITED STATES	6-Sep-05	IA Correspondence	Meeting/Telecon	Info		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
161510 UNITED STATES	7-Sep-05	IA Correspondence	Meeting/Telecon	Info	Power Point Slide presentation for 8-SEP-05 meeting.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160923 UNITED STATES	25-Aug-05	IA Correspondence	Meeting/Telecon	Info	Additional questions.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160790 UNITED STATES	24-Aug-05	IA Correspondence	Gen Corr		Acknowledged e-mail receipt.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
160789 UNITED STATES	24-Aug-05	IA Correspondence	Response to	Information Request	Provide list of questions requested by the Agency.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

160768 UNITED STATES	23-Aug-05	IA Correspondence	Gen Corr		Will provide information requested on 22-AUG-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
160767 UNITED STATES	22-Aug-05	IA Correspondence	Request	Info	Provide a word document with questions on page 10-11 of the 7-14-05 briefing document.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
160520 UNITED STATES	18-Aug-05	IA Correspondence	Meeting/Telecon	Meeting-Request	FDA CMC pilot program		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
160428 UNITED STATES	11-Aug-05	IA Correspondence	CMC Issues	Other	Request to participate in the Agency's CMC pilot program.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
160385 UNITED STATES	11-Aug-05	IDA-FDA Con Rpt	Phone	CMC Issues	FDA CMC pilot program.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
160219 UNITED STATES	11-Aug-05	IA Correspondence	Meeting/Telecon	Info	PDF copy of 11-AUG-05 formal written request to participate in FDA CMC pilot program.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
160061 UNITED STATES	4-Aug-05	IA Correspondence	Pediatric Exclus	Issues	Submission feedback letter received.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
159810 UNITED STATES	3-Aug-05	IA Correspondence	Gen Corr		Submission feedback	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
159193 UNITED STATES	25-Jul-05	IA Correspondence	Request	Info	Pediatric Waiver and Deferral S/N 223.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
159143 UNITED STATES	14-Jul-05	IA Correspondence	Meeting/Telecon	Minutes	Meeting/Telecon held on 15-JUN-05.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
159132 UNITED STATES	22-Jul-05	IA Correspondence	Meeting/Telecon	Confirm	Type B meeting confirmed for 8-AUG-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
159067 UNITED STATES	20-Jul-05	IA Correspondence	Meeting/Telecon	Mtg Req-Response	Meeting granted 9-8-05.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
157526 UNITED STATES	20-Jun-05	IA Correspondence	Meeting/Telecon	Minutes	Quality by Design approach meeting 15-JUN-05.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156906 UNITED STATES	14-Jun-05	IA Correspondence	Response to	Review/Comment Req	Drug interaction study development plan.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
156155 UNITED STATES	2-Jun-05	IA Correspondence	Gen Corr		Notification of the requested data on 217, 219 & 226.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155909 UNITED STATES	27-May-05	IA Correspondence	Request	Other	Desk copies of 1/11, 1/14 and 2/1/2005 submissions.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
155760 UNITED STATES	27-May-05	IDA-FDA Con Rpt	Phone	CMC Issues	Inclusion of Executed Batch Records, Sustained versus Extended Release terminology.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
154410 UNITED STATES	4-May-05	IA Correspondence	Gen Corr		Submission feedback.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
154274 UNITED STATES	22-Apr-05	IA Correspondence	Meeting/Telecon	Confirm	15-JUN-05 to discuss Quality by Design approach.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
153604 UNITED STATES	22-Apr-05	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues	Meeting scheduled for 15-JUN-05 to discuss ICH Q8 "Quality by Design" approach and its applicability to upcoming NDA		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

153543 UNITED STATES	21-Apr-05	IA Correspondence	Request	Guidance	Feedback on submission S/N 223 & 242.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
152354 UNITED STATES	1-Apr-05	IA Correspondence	Meeting/Telecon	Meeting-Request	Meeting to discuss Wyeth's proposal for 'Quality by Design Approach'.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
151769 UNITED STATES	21-Mar-05	IA Correspondence	Meeting/Telecon	Meeting-Request	Discuss ICHQ8 Risk Based Approach.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
149932 UNITED STATES	16-Feb-05	IA Correspondence	Gen Corr		FDA Feedback.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
149707 UNITED STATES	15-Feb-05	IA Correspondence	Clinical Issues	Other	Requests and recommendations on submissions S/N 151 & 161.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148959 UNITED STATES	28-Jan-05	IA Correspondence	Meeting/Telecon	Other	Meeting cancelled 31-JAN-05.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148748 UNITED STATES	11-Jan-05	IA Correspondence	Meeting/Telecon	Request - Other	Requesting 21-JAN-05 meeting attendees names	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148746 UNITED STATES	12-Jan-05	IA Correspondence	CMC Issues	Information-Request	Additional information requested 11-JAN-05 Teleconference.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148718 UNITED STATES	11-Jan-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148389 UNITED STATES	19-Jan-05	IA Correspondence	Gen Corr		e-mail received and able to view the document.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
148343 UNITED STATES	18-Jan-05	IA Correspondence	Response to	Information Request	12-JAN-05 Info request	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147992 UNITED STATES	11-Jan-05	IA Correspondence	Meeting/Telecon	Info	List of participants in the 11-JAN-05 telecon.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147991 UNITED STATES	12-Jan-05	IA Correspondence	Response to	Information Request	Additional information requested on the 11-JAN-05 telecon.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147975 UNITED STATES	6-Jan-05	IA Correspondence	Meeting/Telecon	Meeting-Request	To clarify the submitted IVIVC.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
147938 UNITED STATES	11-Jan-05	IDA-FDA Con Rpt	Phone	CMC Issues	Additional information in support of January 21 Type B meeting for Biowaiver for 150 mg.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
145060 UNITED STATES	15-Nov-04	IA Correspondence	Gen Corr		Concur with the DRUDP's review.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
144821 UNITED STATES	8-Nov-04	IA Correspondence	CMC Issues	Information-Request	Seeking confirmation of designation of Methoxyacetate as starting material.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
144820 UNITED STATES	9-Nov-04	IDA-FDA Con Rpt	Phone	CMC Issues	Confirmation of designation of Methoxyacetate as starting material.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
144818 UNITED STATES	5-Nov-04	Pre-IDA FDA Cont Rpt	Other		Issues regarding S/N 144.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
144059 UNITED STATES	22-Oct-04	IA Correspondence	Request	Review/Comment	Feecdback on submission dated 21-JUL-0-4 (S/N 169).	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

143938 UNITED STATES	25-Oct-04	IA Correspondence	Clinical Issues	Info Request-Respon	Comments on the submissions dated 21-JUL-04 and 16-SEP-04.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143244 UNITED STATES	12-Oct-04	IDA-FDA Con Rpt	Phone	Pediatric Ex Issues	Requirements for a Pediatric development program.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143125 UNITED STATES	22-Sep-04	IA Correspondence	Request	Info	Question on the future product labeling.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
143124 UNITED STATES	6-Aug-04	IA Correspondence	Request	Info	Status of FDA feedback on submissions S/N 146 and 157.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142639 UNITED STATES	21-Sep-04	IA Correspondence	Gen Corr				Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142495 UNITED STATES	28-Sep-04	IA Correspondence	Response to	Information Request	FDA cannot comment on how Wyeth discontinuation scale will impact labeling	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142088 UNITED STATES	21-Sep-04	IA Correspondence	Response to	Review/Comment Req	Feedback on the S/N 157 and 146.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142086 UNITED STATES	21-Sep-04	IA Correspondence	Response to	Review/Comment Req	Response to status of submissions dated 02-JUN-04, 17-JUN-04 & 21-JUL-04.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
142003 UNITED STATES	20-Sep-04	IA Correspondence	Request	Review/Comment	Request for status of submissions dated 02-JUN-04, 17-JUN-04 & 21-JUL-04.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
140230 UNITED STATES	6-Aug-04	IA Correspondence	Request	Info	Status of FDA feedback on submissions S/N 149 and 157.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
139714 UNITED STATES	16-Jun-04	IA-GRR Note to File	Other		NO DOC		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
139385 UNITED STATES	12-Jul-04	IA Correspondence	Gen Corr		FDA waiting for feedback from the Cardio consultants to respond to our request for feedback.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
139204 UNITED STATES	8-Jul-04	IA Correspondence	Request	Review/Comment	Requested feedback on our proposed QTc clinical study.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138945 UNITED STATES	29-Jun-04	IA Correspondence	Gen Corr		Submission (1-27-04) recommendations and comments from the Office of Biometrics	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134449 UNITED STATES	28-Jan-04	IA Correspondence	Pediatric Exclus	Issues	Question about pediatric written requests for MDD studies	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
138335 UNITED STATES	7-Jun-04	IDA-FDA Con Rpt	Phone	Other	Request for feedback on draft QT protocol.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
137426 UNITED STATES	12-May-04	IDA-FDA Con Rpt	Phone	Clinical Issues	Request for feedback on a draft QT protocol.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
137248 UNITED STATES	23-Feb-04	IA Correspondence	Pediatric Exclus	Issues	Documents received	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
136123 UNITED STATES	6-Nov-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
135827 UNITED STATES	1-Apr-04	IA Correspondence	Request	Info		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

126366 UNITED STATES	30-Jul-03	IA Correspondence	Protocol-Clinical	Other	FDA completed review of April 1, 2003 submission and have recommendations regarding findings in the fertility and development toxicity study in rats.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
126135 UNITED STATES	11-Jul-02	IA Correspondence	Response to	Review/Comment Req	response to Serial 008	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
199844 UNITED STATES	15-May-07	IA Correspondence	Clinical Issues	Info Request-Respon	Comments regarding Statistical plan.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108454 UNITED STATES	3-May-02	IA Correspondence	Response to	Information Request		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108452 UNITED STATES	2-May-02	IA Correspondence	CMC Issues	Information-Request		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108451 UNITED STATES	1-May-02	IA Correspondence	CMC Issues	Info Request-Respon		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108448 UNITED STATES	29-Apr-02	IA Correspondence	CMC Issues	Information-Request		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108441 UNITED STATES	25-Apr-02	IA Correspondence	CMC Issues	Info Request-Respon		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108444 UNITED STATES	26-Apr-02	IA Correspondence	CMC Issues	Info Request-Respon		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
108440 UNITED STATES	23-Apr-02	IA Correspondence	CMC Issues	Other		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
107582 UNITED STATES	11-Jun-02	IA Correspondence	Perm to Proceed				Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
135485 UNITED STATES	22-Mar-04	IA Correspondence	Response to	Other	Missed Serial #120 - Should be no problem	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
135357 UNITED STATES	19-Mar-04	IA Correspondence	Gen Corr		Inform FDA that there will no serial #120	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
135048 UNITED STATES	8-Mar-04	IA Correspondence	Gen Corr		Clinical and Pharm/Tox comments	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134991 UNITED STATES	3-Mar-04	IA Correspondence	Prot Amend	Revised		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134982 UNITED STATES	3-Mar-04	IA Correspondence	Response to	Information Request	Request clarification to 2/25 e-mail	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134982 UNITED STATES	3-Mar-04	IA Correspondence	Gen Corr		Request clarification to 2/25 e-mail	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134682 UNITED STATES	25-Feb-04	IA Correspondence	Safety Issues	Other	re: Safety Concern Issues; FDA Review of Prot - Perm to Proceed	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134682 UNITED STATES	25-Feb-04	IA Correspondence	Perm to Proceed		re: Safety Concern Issues; FDA Review of Prot - Perm to Proceed	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134524 UNITED STATES	6-Feb-04	IDA-FDA Con Rpt	Other		FDA waiting for a desk copy	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

134306 UNITED STATES	5-Feb-04	IA Correspondence	Gen Corr		Increase dose from 200mg to 400 mg	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134514 UNITED STATES	5-Feb-04	IA Correspondence	Gen Corr			######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134409 UNITED STATES	13-Feb-04	IA Correspondence	Other		Dose adjustment	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
134153 UNITED STATES	13-Feb-04	IA Correspondence	Gen Corr		Urgent Feedback sent to FDA	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
132252 UNITED STATES	25-Nov-03	IA Correspondence	Meeting/Telecon	Minutes	Nov 6th mtg		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
125568 UNITED STATES	24-Jul-03	IA Correspondence	Info Amend-Pharm/Tox		FDA's OCPB teams has completed their review of Wyeth's submission of 5/29/03 providing follow-up responses and have found Wyeth's plans reasonable regarding population pharmacokinetic analyses and elderly PK using traditional PK methods.	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
124568 UNITED STATES	10-Apr-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
124244 UNITED STATES	19-May-03	IA Correspondence	Protocol-Clinical	Info Request-Respon	permission to proceed	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
123103 UNITED STATES	11-Jun-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
123016 UNITED STATES	9-Jun-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
122628 UNITED STATES	28-May-03	IA Correspondence	Request	Review/Comment		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
122336 UNITED STATES	28-May-03	IA Correspondence	Other		Wyeth seeks to speak to statistical reviewer regarding comment on multiplicity.	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
121328 UNITED STATES	17-Apr-03	IA Correspondence	Meeting/Telecon	Minutes		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
133148 UNITED STATES	21-Jan-04	IA Correspondence	Pediatric Exclus	Written Request	Questions about Pediatric Written Requests for MDD Studies	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
121327 UNITED STATES	4-Apr-03	IA Correspondence	Meeting/Telecon	Info	corrected background info., participants list and mtg questions	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
120785 UNITED STATES	22-Apr-03	IA Correspondence	Meeting/Telecon	Minutes	Ackn Rcpt - April 10, 2003 Mtg Minutes		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117876 UNITED STATES	20-Feb-03	IA Correspondence	Request	Review/Comment		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117857 UNITED STATES	31-Jan-03	IA Correspondence	Response to	Information Request		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
117855 UNITED STATES	29-Jan-03	IA Correspondence	Response to	Information Request		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

117654 UNITED STATES	3-Mar-03	IA Correspondence	Meeting/Telecon	Minutes	FDA Mtg Minutes - EOP2 02/04/03 Mtg	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
116920 UNITED STATES	29-Jan-03	IA Correspondence	Gen Corr		FDA sent e-mail confirming receipt of Wyeth's response to FDA Request for Pharma cokinetic data (serial no. 041)	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115093 UNITED STATES	6-May-02	IA Correspondence	Gen Corr		request for clarification forwarded	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
131579 UNITED STATES	12-Nov-03	IA Correspondence	CMC Issues	Other	FDA comments on May 29th and Sept. 3rd, 5th and 8th submissions		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
130423 UNITED STATES	12-Nov-03	IA Correspondence	Response to	Review/Comment Req	re: submission on May 29, Sep 3, 5, & 8	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
129384 UNITED STATES	23-Sep-03	IA Correspondence	Protocol-Clinical	Other	comments and recommendations regarding 3151A1-303-WWW for the SR	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
129372 UNITED STATES	23-Sep-03	IA Correspondence	Protocol-Clinical	Other	comments and recommendations regarding 3151A1-303-WWW for the SR		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
128997 UNITED STATES	9-Oct-03	IDA-FDA Con Rpt	Phone	CMC Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
128416 UNITED STATES	15-Apr-03	IA-GRR Note to File	Other		NO DOC		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
128356 UNITED STATES	23-Sep-03	IA Correspondence	Request	Review/Comment	looking for feedback on Serial 069	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
128112 UNITED STATES	12-Sep-03	IA Correspondence	Response to	Information Request	response to clinical portion (serial no. 065) attached as pdf	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
128104 UNITED STATES	12-Sep-03	IA Correspondence	Response to	Information Request	response to: when will we receive comments on serial 069?	######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
127909 UNITED STATES	12-Sep-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
122269 UNITED STATES	19-May-03	IA Correspondence	Protocol-Clinical	Info Request-Respon	Permission to proceed with comments on 3 new protocols		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114726 UNITED STATES	6-Dec-02	IA Correspondence	Meeting/Telecon	Request-Response		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114725 UNITED STATES	6-Dec-02	IA Correspondence	Meeting/Telecon	Response Req - Other		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114517 UNITED STATES	2-Dec-02	IA Correspondence	Meeting/Telecon	Confirm		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
110596 UNITED STATES	13-Aug-02	IA Correspondence	Prot Amend	Change in Prot		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
109361 UNITED STATES	26-Apr-02	IA Correspondence	CMC Issues	Info Request-Respon		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
109360 UNITED STATES	26-Apr-02	IA Correspondence	CMC Issues	Information-Request		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

108742 UNITED STATES	8-May-02	IA Correspondence	Response to	Information Request		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
108561 UNITED STATES	24-Jun-02	IDA-FDA Con Rpt	Phone	Pediatric Ex Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116592 UNITED STATES	15-Jan-03	IA Correspondence	Protocol - Non-Clin	Other	Wyeth is seeking advice whether background information and proposed protocols can be submitted under one serial number for each protocol	######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116588 UNITED STATES	23-Jan-03	IA Correspondence	Meeting/Telecon	Info		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116581 UNITED STATES	16-Jan-03	IA Correspondence	Response to	Guidance Request		######	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116434 UNITED STATES	30-Jan-03	IDA-FDA Con Rpt	Phone	Safety Issues	FDA has safety concerns regarding DVS-233 SR Tablets regarding proposed dose levels due to observations of tachycardia & hypertension. FDA requested pharmacokinetic stead-state profiles of DVS-223 SR tablets data & simulated profiles for 100, 200 & 400 mg doses.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116197 UNITED STATES	28-Jan-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116097 UNITED STATES	24-Jan-03	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
116080 UNITED STATES	22-Jan-03	IA Correspondence	Meeting/Telecon	Info		######	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
107582 UNITED STATES	11-Jun-02	IA Correspondence	Clinical Issues	Other			Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
106840 UNITED STATES	4-Jun-02	IDA-FDA Con Rpt	Phone	Pediatric Ex Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
106840 UNITED STATES	4-Jun-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105903 UNITED STATES	10-May-02	IDA-FDA Con Rpt	Phone	General	IND in effect		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105893 UNITED STATES	8-May-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105891 UNITED STATES	8-May-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105880 UNITED STATES	6-May-02	IA Correspondence	Response to	Information Request			Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
105833 UNITED STATES	2-May-02	IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
107620 UNITED STATES	4-Jun-02	IA Correspondence	Clinical Issues	Other	re: Clinical Trial Data Bank		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US
107628 UNITED STATES	19-Jun-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ	US

107582 UNITED STATES	11-Jun-02	IA Correspondence	Pediatric Exclus	Waiver Req-Respon		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105190 UNITED STATES	18-Apr-02	IA Correspondence	Response to	Information Request	Additional Copy of Initial IND	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105414 UNITED STATES	22-Apr-02	IA Correspondence	CMC Issues	Other		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105191 UNITED STATES	18-Apr-02	IA Correspondence	Initial IDA	Other	Requesting Additional Copies of IND	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105191 UNITED STATES	18-Apr-02	IA Correspondence	Request	Info	Requesting Additional Copies of IND	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105312 UNITED STATES	18-Apr-02	IA Correspondence	Initial IDA	Acknowledge Receipt		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105314 UNITED STATES	25-Apr-02	IA Correspondence	Initial IDA	Issues	re: Incorrect receipt date	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US
105319 UNITED STATES	26-Apr-02	IA Correspondence	Initial IDA	Issues	re: Incorrect Receipt Date	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S`PRISTIQ	US

Grits Doc ID	App. Country	Doc. Date	Reference #	Doc. Type	Sub1 Type	Sub2 Type	Sub3 Type	Chronology Description	Email Date	To	From	App. #	App. Description	App. Region	Corporate Tradename	App. Country Abbrev.
162838	UNITED STATES	27-Sep-05		MA-FDA C	Phone	General		NDA number assigned.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
163294	UNITED STATES	11-Oct-05		MA-Corres	Request	Info		Feedback requested.	11-Oct-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
164424	UNITED STATES	1-Nov-05		MA-FDA C	Phone	General		Outstanding NDA items.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
164844	UNITED STATES	9-Nov-05		MA-Corres	Resp to Re	Info		Agency requests a literature search.	9-Nov-05	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
164931	UNITED STATES	9-Nov-05		MA-FDA C	Phone	General		Literature search.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
170885	UNITED STATES	9-Nov-05		MA-User F	Payment	Submission				FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
165026	UNITED STATES	12-Nov-05		MA-Corres	General	Corresp		Preclinical TOC and ECG tracings.	12-Nov-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
167353	UNITED STATES	22-Dec-05		MA-Corres	General	Corresp		Delivery and Holiday week notification.	22-Dec-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

167099	UNITED STATES	22-Dec-05	MA-(Origin	Orig Full Subm			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
167350	UNITED STATES	28-Dec-05	MA-Corres	Mtg/Teleco Request for Meeting	Schedule training session for eCTD.	28-Dec-05	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
167351	UNITED STATES	29-Dec-05	MA-Corres	Mtg/Teleco Info	Saved date of 8-FEB-2006 for training session of eCTD.	29-Dec-05	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
167352	UNITED STATES	31-Dec-05	MA-Corres	Mtg/Teleco Other	Will confirm details after meeting the eCTD team.	31-Dec-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
167696	UNITED STATES	11-Jan-06	MA-Corres	Mtg/Teleco Request - Other	Requests and questions prior to the meeting on 8-FEB-2006.	11-Jan-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168112	UNITED STATES	20-Jan-06	MA-Corres	Resp to Re Info	Answers to questions 1 through 5.	20-Jan-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
206335	UNITED STATES	20-Jan-06	MA-Corres	General Corresp	Acknoledged receipt of e-mail.	20-Jan-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168114	UNITED STATES	23-Jan-06	MA-Corres	Request Other	Request additional 8 desk copies for the meeting to be held on 13-FEB-2006.	23-Jan-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168130	UNITED STATES	23-Jan-06	MA-Corres	Mtg/Teleco Request for Meeting	Pilot Program Meeting.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

168828	UNITED STATES	1-Feb-06	MA-FDA C	Phone	CMC Issues	Pilot Program.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168794	UNITED STATES	1-Feb-06	MA-Corres	Mtg/Teleco	Request for Meeting	eCTD sequence No. 0001 - Pilot program.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168849	UNITED STATES	3-Feb-06	MA-Corres	Mtg/Teleco	Other	Question and comments regarding the meeting logistics.	3-Feb-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168939	UNITED STATES	3-Feb-06	MA-Corres	Resp to Re	Info	8-FEB-2006 meeting.	3-Feb-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168934	UNITED STATES	3-Feb-06	MA-FDA C	Phone	CMC Issues	Pilot Program meeting.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168934	UNITED STATES	3-Feb-06	MA-FDA C	Phone	Meeting Sched/Issues	Pilot Program meeting.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
168940	UNITED STATES	6-Feb-06	MA-Corres	Request	Other	Permission to enter the conference room 10-15 minutes earlier.	6-Feb-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
169110	UNITED STATES	7-Feb-06	MA-Corres	Resp to Re	Other	Room reservation made earlier than scheduled meeting time.	7-Feb-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
169303	UNITED STATES	9-Feb-06	MA-FDA C	Phone	CMC Issues	Coordinate submission package for the 8-MAR-2006 meeting.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

169719	UNITED STATES	10-Feb-06	MA-FDA C	Phone	CMC Issues	Agency's request for raw data sets.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
169666	UNITED STATES	14-Feb-06	MA-Corres	Request	Other	Approval of Dual proprietary name.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
171268	UNITED STATES	16-Feb-06	MA-Corres	Mtg/Teleco	Confirm	8-MAR-2006.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
169644	UNITED STATES	16-Feb-06	MA-Corres	Mtg/Teleco	Background Pkg	CMC Pilot Program meeting scheduled 8-MAR-06.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
169796	UNITED STATES	17-Feb-06	MA-FDA C	Phone	CMC Issues	Agency's request for raw data sets.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
169797	UNITED STATES	17-Feb-06	MA-FDA C	Phone	CMC Issues	Meeting to discuss Agency's questions.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
170047	UNITED STATES	23-Feb-06	MA-Corres	Mtg/Teleco	Confirm	8-MAR-2006 & 13-APR-2006.	23-Feb-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
170274	UNITED STATES	24-Feb-06	MA-FDA C	Phone	CMC Issues	Discuss Wyeth response to the Agency's questions.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
170290	UNITED STATES	24-Feb-06	MA-FDA C	Phone	CMC Issues	Agency's request for raw data sets.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

170679	UNITED STATES	24-Feb-06	MA-Corres	Original Ap	Other	Filing communication.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
170098	UNITED STATES	27-Feb-06	MA-Corres	Original Ap	Acknowledge Receipt		27-Feb-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
170451	UNITED STATES	28-Feb-06	MA-FDA C	Phone	CMC Issues	FDA CMC Pilot program meeting scheduled for 8-MAR-2006.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182003	UNITED STATES	28-Feb-06	MA-Corres	Mtg/Teleco	Info	List of attendees for 8-MAR-2006 meeting.	28-Feb-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
170473	UNITED STATES	3-Mar-06	MA-Corres	Mtg/Teleco	Info	List of attendees for meeting 8-MAR-2006.	3-Mar-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
170875	UNITED STATES	3-Mar-06	MA-FDA C	Phone	CMC Issues	Environmental assessment section for NDA.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
170655	UNITED STATES	7-Mar-06	MA-Corres	Amendmer	Other	Raw data sets used to develop the IVIVC. eCTD sequence 0004.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182015	UNITED STATES	7-Mar-06	MA-Corres	Mtg/Teleco	Info	Copies of the presentation.	7-Mar-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
171345	UNITED STATES	16-Mar-06	MA-Corres	Amendmer	Other	Confidential and Non-Confidential Environmental Assessment.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

171423	UNITED STATES	16-Mar-06	MA-Corres	Mtg/Teleco	Minutes	Pilot program meeting 8-MAR-2006.	16-Mar-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
172309	UNITED STATES	24-Mar-06	MA-FDA C	Phone	CMC Issues	Drug product samples for reviewer.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
172158	UNITED STATES	24-Mar-06	MA-Corres	Mtg/Teleco	Request - Other	Updated version of slides for meeting 8-Mar-2006. Also need samples of each strength.	24-Mar-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
172162	UNITED STATES	24-Mar-06	MA-Corres	Mtg/Teleco	Req Response- Other	Copy of slides presented at 8-Mar-2006 meeting.	24-Mar-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
172825	UNITED STATES	7-Apr-06	MA-FDA C	Phone	Clinical Issues	Clinical Pharmacology Review.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
172826	UNITED STATES	7-Apr-06	MA-FDA C	Phone	CMC Issues	Pilot program meeting 13-APR-2006. Meeting held 8-MAR-2006 to discuss additional CMC information as part of the CMC pilot program.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173287	UNITED STATES	7-Apr-06	MA-Corres	Mtg/Teleco	Minutes			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
172986	UNITED STATES	10-Apr-06	MA-FDA C	Phone	Clinical Issues	Clinical site and sponsor inspections.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173018	UNITED STATES	11-Apr-06	MA-Corres	Request	Info	Provide answers to aid in the review of the application.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

173614	UNITED STATES	21-Apr-06	MA-Corres	Safety Upd	Other	Four Month update.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173615	UNITED STATES	21-Apr-06	MA-Corres	Resp to Re	Info	Data from clinical investigators who participated in the study.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173871	UNITED STATES	25-Apr-06	MA-Corres	General Corresp		Acknowledged receipt of the 1572s.	25-Apr-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173873	UNITED STATES	25-Apr-06	MA-Corres	General Corresp		Recent submissions.	25-Apr-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173895	UNITED STATES	25-Apr-06	MA-Corres	Resp to Re	Info	Recent submissions issues. 21-APR-2006 submission is not yet available.	25-Apr-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
173880	UNITED STATES	25-Apr-06	MA-Corres	Resp to Re	Info	Provide the 1572s requested by the Agency.	25-Apr-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
174224	UNITED STATES	27-Apr-06	MA-FDA C	Phone	Other	QBR template questions.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
174176	UNITED STATES	28-Apr-06	MA-Corres	Amendmer	Other	Provide comparability protocol for the implementation of PAT.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
174798	UNITED STATES	5-May-06	MA-Corres	Resp to Re	Review/Comment			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

174764	UNITED STATES	8-May-06	MA-User F	Information-Request	Official user fee action date.	8-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
208584	UNITED STATES	8-May-06	MA-Corres	Request Info	Copy of the IR letter.	8-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
174784	UNITED STATES	8-May-06	MA-Corres	Resp to Re Info	IR letter issued on 5-MAY-2006.	8-May-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
174861	UNITED STATES	9-May-06	MA-Corres	Resp to Re Info	User fee action date is 22-OCT-2006.	9-May-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
174879	UNITED STATES	10-May-06	MA-Corres	Amendmer Issues	Completed question based review template.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
175432	UNITED STATES	16-May-06	MA-FDA C	Phone CMC Issues	Pilot program meeting 23-MAY-2006.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
175284	UNITED STATES	17-May-06	MA-Corres	General Corresp	Replacement of damaged media.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
175343	UNITED STATES	18-May-06	MA-Corres	General Corresp	QBR template response.	18-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
175566	UNITED STATES	22-May-06	MA-Corres	Resp to Re Info	(5) compact disc review copies of the 10-MAY-2006 submission.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

176104	UNITED STATES	22-May-06	MA-Corres	General Corresp		Replacement of CD.	22-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
207881	UNITED STATES	22-May-06	MA-Corres	Request	Info	5 CD copies of the 10-MAY-2006 submission.	22-May-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176455	UNITED STATES	6-Jun-06	MA-Corres	Request	Info	Requesting a copy of Data sets for 2-year carcinogenicity studies.	6-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176593	UNITED STATES	7-Jun-06	MA-FDA C	Phone	CMC Issues	Discuss questions on IVIVC.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176594	UNITED STATES	7-Jun-06	MA-Corres	Request	Info	Stat requestsl.	7-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176572	UNITED STATES	7-Jun-06	MA-Corres	General Corresp		Tradename request: Elifore.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176706	UNITED STATES	9-Jun-06	MA-Corres	General Corresp		Miscellaneous issues.	9-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176701	UNITED STATES	9-Jun-06	MA-Corres	Data	Data Sets Req-Respor	Mice and rats carcinogenicity studies.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
176946	UNITED STATES	12-Jun-06	MA-FDA C	Phone	CMC Issues	Request for recalculation of IVIVC data.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

177288	UNITED STATES	15-Jun-06	MA-Corres	Request	Info	September's advisory committee.	15-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177289	UNITED STATES	15-Jun-06	MA-Corres	General Corresp		September's advisory committee.	15-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177291	UNITED STATES	15-Jun-06	MA-Corres	General Corresp			15-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177487	UNITED STATES	16-Jun-06	MA-Corres	Resp to Re	Info	Questions regarding blood pressure.	16-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177486	UNITED STATES	16-Jun-06	MA-Corres	Request	Info	Advisory committee information.	16-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177570	UNITED STATES	16-Jun-06	MA-Corres	Report [No	Other	Need to follow the guidance on page 61. 2- yr carcinogenicity studies.	21-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177665	UNITED STATES	21-Jun-06	MA-Corres	Request	Info	Carcinogenicity studies.	21-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177753	UNITED STATES	22-Jun-06	MA-Corres	Request	Info	September advisory committee meeting background information.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
177852	UNITED STATES	26-Jun-06	MA-Corres	Inspection	Notice	Investigator files associated with study 306.	26-Jun-06	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

177862	UNITED STATES	26-Jun-06	MA-Corres	Amendmer	Other	Recalculated IVIVC information.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178420	UNITED STATES	26-Jun-06	MA-Corres	Resp to Re	Info	Care Data Set qyestions and responses.	26-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178415	UNITED STATES	27-Jun-06	MA-Corres	Request	Info		27-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178458	UNITED STATES	28-Jun-06	MA-Corres	Request	Info	Stat request.	28-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178397	UNITED STATES	3-Jul-06	MA-Corres	Resp to Re	Info	Minor amendment CMC.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178624	UNITED STATES	6-Jul-06	MA-Corres	Request	Info		6-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178645	UNITED STATES	6-Jul-06	MA-Corres	Request	Guidance	Feedback regarding medical questions.	6-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178625	UNITED STATES	7-Jul-06	MA-Corres	Resp to Re	Info	Information will be provided next week.	7-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
178649	UNITED STATES	7-Jul-06	MA-Corres	General Corresp		Inform the Agency eCTD has been loaded into the server.	7-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

178646	UNITED STATES	7-Jul-06	MA-Corres	Request Info	Carcinogenicity data sets.	7-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
178862	UNITED STATES	10-Jul-06	MA-Corres	General Corresp	Re-confirmed NDA numbers.	10-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
178864	UNITED STATES	10-Jul-06	MA-Corres	General Corresp	Clarification of NDA numbers.	10-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
178867	UNITED STATES	10-Jul-06	MA-Corres	General Corresp	Correction - Typographical error.	10-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
178856	UNITED STATES	12-Jul-06	MA-Corres	General Corresp	Revised version of the requests for info.	12-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
178969	UNITED STATES	13-Jul-06	MA-Corres	Mtg/Teleco Request - Other	Reminder to send list of investigators/Briefing materials.	13-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
178910	UNITED STATES	13-Jul-06	MA (Pend)	Clinical	Response to statistical queries.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179047	UNITED STATES	14-Jul-06	MA-Corres	Resp to Re Other	Statistical queries.	14-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179488	UNITED STATES	14-Jul-06	MA-Corres	Fed Regist Other		14-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

179236	UNITED STATES	17-Jul-06	MA-Corres| Mtg/Teleco Minutes	Minutes of 23-MAY-2006.	17-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179430	UNITED STATES	20-Jul-06	MA-Corres| Mtg/Teleco Info	Meeting date changed to 7-SEP-2006.	20-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179827	UNITED STATES	27-Jul-06	MA-Corres| Request Info	Requesting Carcinogenicity Data sets.	27-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179828	UNITED STATES	27-Jul-06	MA-Corres| Resp to Re Info	Expect to send the Carcinogenicity Data Sets Monday 31-JUL-2006.	27-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179877	UNITED STATES	27-Jul-06	MA-Corres| Mtg/Teleco Other	Acknowledged receipt of date change.	27-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179875	UNITED STATES	27-Jul-06	MA-Corres| Mtg/Teleco Info	Date for meeting has been changed to 7-SEPT-2006.	27-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
179953	UNITED STATES	31-Jul-06	MA-Corres| Amendmer Other	Re-submission of mouse and rat Carcinogenicity datasets.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180145	UNITED STATES	2-Aug-06	MA-Corres| General Corresp	CAC Data Sets.	2-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180380	UNITED STATES	3-Aug-06	MA-Corres| Mtg/Teleco Background Pkg	7-SEP-2006 PDAC meeting.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

180525	UNITED STATES	7-Aug-06	MA-Corres	Clinical Issı	Other	Population PK analyses.	7-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180526	UNITED STATES	7-Aug-06	MA-Corres	Mtg/Teleco	Info	Briefing book for 7-SEP-2006 Advisory Committee Meeting.	7-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180571	UNITED STATES	7-Aug-06	MA-Corres	General Corresp		Agency will confirm package arrival.	7-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180572	UNITED STATES	7-Aug-06	MA-Corres	Request	Info	Resend and/or fax Investigator/Briefing materials.	7-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180573	UNITED STATES	7-Aug-06	MA-Corres	General Corresp			7-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180574	UNITED STATES	7-Aug-06	MA-Corres	General Corresp			7-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180575	UNITED STATES	7-Aug-06	MA-Corres	Clinical Issı	Other	Population PK feedback issues.	7-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180576	UNITED STATES	7-Aug-06	MA-Corres	Request	Info	Statistical analyses of studies 309 and 320.	7-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
180816	UNITED STATES	9-Aug-06	MA-Corres	General Corresp		Population PK feedback	9-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

181486	UNITED STATES	11-Aug-06	MA-Corres	General Corresp		Message from Yaning.	11-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181223	UNITED STATES	16-Aug-06	MA-Corres	Mtg/Teleco	Background Pkg-issue	7-SEP-2006 Drug Advisory Committee meeting.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181424	UNITED STATES	21-Aug-06	MA-Corres	General Corresp		Assembly of data sets.	21-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181479	UNITED STATES	21-Aug-06	MA-Corres	Mtg/Teleco	Info	Telephone information for the teleconference.	21-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181476	UNITED STATES	21-Aug-06	MA-Corres	Mtg/Teleco	Info	List of attendees.	21-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181848	UNITED STATES	25-Aug-06	MA-Corres	General Corresp		Extension letter.	25-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181949	UNITED STATES	28-Aug-06	MA-Corres	General Corresp		Formatting issues.	28-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
181941	UNITED STATES	28-Aug-06	MA-FDA C	Phone	CMC Issues	FDA request for raw data sets and electronic copy of presentation during the pre-approval inspection of Guyama.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182009	UNITED STATES	29-Aug-06	MA-Corres	Data	Data Sets Req-Respor	Datasets appear to be acceptable.	29-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

182046	UNITED STATES	29-Aug-06	MA-FDA C	Phone	Non-Clinical Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182142	UNITED STATES	30-Aug-06	MA-Corres	General Corresp		Various issues.	30-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182140	UNITED STATES	31-Aug-06	MA-Corres	General Corresp		DPP has extended the UF date by 3 months.	31-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182310	UNITED STATES	31-Aug-06	MA-Corres	Amendmer	Other	Response to request for statistical analyses.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182347	UNITED STATES	1-Sep-06	MA-Corres	Mtg/Teleco	Info	Electronic copies of the pre-approval inspection in Guyama, PR.	1-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182419	UNITED STATES	5-Sep-06	MA-Corres	General Corresp		PAI introductory presentation - part 1.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182422	UNITED STATES	5-Sep-06	MA-Corres	General Corresp		PAI introductory presentation - part 2.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182424	UNITED STATES	5-Sep-06	MA-Corres	General Corresp		PAI introductory presentation - part 3.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
182425	UNITED STATES	5-Sep-06	MA-Corres	General Corresp		PAI introductory presentation - part 4.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

182426	UNITED STATES	5-Sep-06	MA-Corres| General Corresp	PAI introductory presentation - part 1a.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
182427	UNITED STATES	5-Sep-06	MA-Corres| General Corresp	PAI introductory presentation - part 4a.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
182428	UNITED STATES	5-Sep-06	MA-Corres| General Corresp	PAI introductory presentation - part 4b.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
182441	UNITED STATES	5-Sep-06	MA-Corres| Resp to Re Info	Nonmen Code and Data Sets.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
183083	UNITED STATES	14-Sep-06	MA-Corres| Resp to Re Info	Status of submissions.	14-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
183122	UNITED STATES	14-Sep-06	MA (Pend)- Request-Response	Correction of population pharmacokinetics calculations.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
183292	UNITED STATES	18-Sep-06	MA-Corres| General Corresp	Withdraw request for dual tradename and proprietary name	18-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
183414	UNITED STATES	19-Sep-06	MA-Corres| Request Info	Feedback on the dual trade name proposal.	19-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
183415	UNITED STATES	19-Sep-06	MA-Corres| Resp to Re Info		19-Sep-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

183442	UNITED STATES	20-Sep-06	MA-Corres	Original Ap	Other	NDA review status.	20-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183436	UNITED STATES	20-Sep-06	MA-FDA C	Phone	CMC Issues	Status of review.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183744	UNITED STATES	21-Sep-06	MA-Corres	Resp to Re	Other	Dual trade names for VMS and MDD	21-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183602	UNITED STATES	22-Sep-06	MA-Corres	Resp to Re	Info	Efficacy and Safety information and analyses.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183607	UNITED STATES	23-Sep-06	MA-Corres	Request	Info	Status and Carcinogenicity review.	23-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183702	UNITED STATES	25-Sep-06	MA-Corres	Resp to Re	Info	Status and carcinogenicity review.	25-Sep-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183802	UNITED STATES	26-Sep-06	MA (Pend)	Other		Withdrawal of Elifore as proposed trade name.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183884	UNITED STATES	27-Sep-06	MA-Corres	General Corresp		Inform the Agency of the Carcinogenicity submission.	27-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
183885	UNITED STATES	27-Sep-06	MA-Corres	General Corresp		Confirmed receipt of e-mail.	27-Sep-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

183886	UNITED STATES	27-Sep-06	MA-Corres	Labeling	Other	Confirmed the last labeling submission dated 21-APR-2006.	27-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184285	UNITED STATES	2-Oct-06	MA-Corres	Resp to Re	Info			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184284	UNITED STATES	2-Oct-06	MA-Corres	Request	Info			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184283	UNITED STATES	2-Oct-06	MA-Corres	Request	Info			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184312	UNITED STATES	3-Oct-06	MA-Corres	Request	Info		3-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184313	UNITED STATES	3-Oct-06	MA-Corres	Resp to Re	Info	Agency is looking for the open label exposure for the B group.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184346	UNITED STATES	3-Oct-06	MA-Corres	Request	Info	Need new carton and container for the new proposed name Pristiq.	3-Oct-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184414	UNITED STATES	4-Oct-06	MA-Corres	Resp to Re	Info	Dates for exposure information and bottle labeling submission.	4-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
184761	UNITED STATES	10-Oct-06	MA-Corres	Resp to Re	Info	Exposure information.	10-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

184779	UNITED STATES	10-Oct-06	MA (Pend)	Clinical		Exposure year data for integrated safety groups B1, B2 and C.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
184981	UNITED STATES	12-Oct-06	MA (Pend)	Labeling		Blister, bottle and carton labeling.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
185123	UNITED STATES	13-Oct-06	MA-Corres	Labeling	Other	Requested revised labels were submitted Thursday, 12-OCT-2006.	13-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
185124	UNITED STATES	16-Oct-06	MA-Corres	General Corresp		Acknowledged receipt of revised labels.	16-Oct-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
185311	UNITED STATES	17-Oct-06	MA-Corres	Request	Info	P/T information.	17-Oct-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
185529	UNITED STATES	18-Oct-06	MA-Corres	Resp to Re	Other	Requested information will be provided to the Agency by 30-OCT-2006.	18-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
185998	UNITED STATES	25-Oct-06	MA-FDA C	Phone	CMC Issues	Status of review of the CMC sections.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
186178	UNITED STATES	25-Oct-06	MA-Corres	Resp to Re	Info	Technical part of the response.	25-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
186179	UNITED STATES	26-Oct-06	MA-Corres	Resp to Re	Info	Historical Control Data.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

186605	UNITED STATES	1-Nov-06	MA (Pend)	CMC		cGMP inspection update.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
186589	UNITED STATES	1-Nov-06	MA-Corres	Inspection	Issues	Guyama, PR manufacturing facility.	1-Nov-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
186994	UNITED STATES	6-Nov-06	MA-Corres	Request	Info	CMC Section.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
187900	UNITED STATES	17-Nov-06	MA-FDA C	Phone	Meeting Sched/Issues	Request for CMC Pilot Program.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
187885	UNITED STATES	17-Nov-06	MA-Corres	General	Corresp	Tradename for DVS.	17-Nov-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
187955	UNITED STATES	20-Nov-06	MA-FDA C	Phone	Meeting Sched/Issues	CMC Pilot Program meeting scheduled for 30-NOV-2006.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
188307	UNITED STATES	22-Nov-06	MA-FDA C	Phone	General	Tradename and review status.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
188889	UNITED STATES	29-Nov-06	MA-Corres	Request	Review/Comment	Request comments on proposed logo.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
189178	UNITED STATES	8-Dec-06	A- MA (Pend)	Request	Response			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

189612	UNITED STATES	12-Dec-06	MA-FDA C	Phone	General	Review status and trade name information.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
189548	UNITED STATES	12-Dec-06	MA-Corres	Request	Concurrence	Concurrence sought for FDA's Antidepressant Written Request Standard.	12-Dec-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
190354	UNITED STATES	15-Dec-06	MA-Corres	Resp to Re	Info	Written request template not available at this time.	15-Dec-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
189786	UNITED STATES	18-Dec-06	MA-FDA C	Phone	CMC Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
190380	UNITED STATES	19-Dec-06	MA-Corres	Pediatric E	Issues	Written request template.	19-Dec-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
190241	UNITED STATES	19-Dec-06	MA-Corres	Mtg/Teleco	Minutes	Minutes of 15-NOV-2006 and 30-NOV-2006.	3-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
190393	UNITED STATES	20-Dec-06	MA-Corres	Labeling	Issues		20-Dec-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
190328	UNITED STATES	21-Dec-06	MA-Corres	Promotiona	Info Request-Respon	Tradename issues.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
190449	UNITED STATES	21-Dec-06	MA-Corres	Labeling	Trade Name Issues			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

190411	UNITED STATES	22-Dec-06	MA-Corres	Pediatric E	Issues		22-Dec-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
190759	UNITED STATES	9-Jan-07	MA-Corres	Resp to Re	Info	FDA will probably not act on this NDA until 22-JAN-2007.	9-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
191069	UNITED STATES	10-Jan-07	MA-FDA C	Phone	CMC Issues	Clarification of action date and November 1 communication on cGMP inspection.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
191005	UNITED STATES	12-Jan-07	MA-Corres	Mtg/Teleco	Minutes	Minutes from the 11-JAN-2007.	12-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
191246	UNITED STATES	17-Jan-07	MA-Corres	Resp to Re	Info	Voice mail message.	17-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
191248	UNITED STATES	17-Jan-07	MA-Corres	General	Corresp		17-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
192069	UNITED STATES	22-Jan-07	MA-Corres	Action Lett	Approvable-Orig App			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
191506	UNITED STATES	22-Jan-07	MA-Corres	General	Corresp	Copy of action letter.	22-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
191727	UNITED STATES	25-Jan-07	MA-Corres	Intent to	Amend	Response to approvable letter.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

191815	UNITED STATES	26-Jan-07	MA-FDA C	Phone	CMC Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
191902	UNITED STATES	29-Jan-07	MA-Corres	General Corresp		Resubmission classification questions.	29-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
191962	UNITED STATES	29-Jan-07	MA-Corres	Resp to Re	Info	Resubmission classification questions.	29-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
192112	UNITED STATES	30-Jan-07	MA-Corres	Labeling	Issues	Combined labeling for both indications MDD and VMS.	30-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
192208	UNITED STATES	30-Jan-07	MA-FDA C	Phone	CMC Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
192339	UNITED STATES	2-Feb-07	MA-Corres	Resp to Re	Info	Clarification to comment #5 under CMC section.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
192374	UNITED STATES	5-Feb-07	MA-Corres	Resp to Re	Info	Label alignment.	5-Feb-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
192589	UNITED STATES	5-Feb-07	MA-FDA C	Phone	CMC Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
192593	UNITED STATES	7-Feb-07	MA-Corres	Labeling	Issues	Additional questions.	7-Feb-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

193202	UNITED STATES	9-Feb-07	MA-Corres|	Resp to Re	Info	Labeling alignment and additional questions.	9-Feb-07	W-AL (Wye	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
193651	UNITED STATES	22-Feb-07	MA-Corres|	Request	Info	Risk Management Plan Questions.	22-Feb-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
194059	UNITED STATES	27-Feb-07	MA-Corres|	CMC Issues		Clarification on what the Reference Listed Drug Name would be.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
194068	UNITED STATES	1-Mar-07	MA-Corres|	Request	Info	Risk management plan questions.	1-Mar-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
194091	UNITED STATES	2-Mar-07	MA-Corres|	Clinical Issu	Info-Request	Responses to Approvable Letter.	2-Mar-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
194215	UNITED STATES	5-Mar-07	MA-Corres|	Resp to Re	Info	Responses to the approvable letter.	5-Mar-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
194353	UNITED STATES	7-Mar-07	MA-Corres|	General Corresp		Risk Management Plan Questions were forwarded to the reviewers.	7-Mar-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
194451	UNITED STATES	8-Mar-07	MA-Corres|	General Corresp		Risk Management Questions information.	8-Mar-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
196445	UNITED STATES	4-Apr-07	MA (Pend)-	Request-Response				FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

196925	UNITED STATES	10-Apr-07	MA-Corres	Clinical Iss	Other	Partial response to the approvable letter.	10-Apr-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
198858	UNITED STATES	30-Apr-07	MA-Corres	CMC Issues		No objections to proposal.	30-Apr-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
199293	UNITED STATES	3-May-07	MA-Corres	Request	Info			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
199338	UNITED STATES	8-May-07	MA-FDA C	Phone	CMC Issues	Pilot program meeting to discuss the IR letter.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
199265	UNITED STATES	8-May-07	MA-Corres	Mtg/Teleco	Info		8-May-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
201251	UNITED STATES	11-May-07	MA-Corres	Request	Review/Comment	Pre-operational review of the PAT process in the CMC facility.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
199725	UNITED STATES	15-May-07	MA-Corres	Request	Info	Feedback on the embryo-fetal study.	15-May-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
200417	UNITED STATES	21-May-07	MA-Corres	Mtg/Teleco	Info	List of attendees for CMC pilot program 22-MAY-2007.	21-May-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
201032	UNITED STATES	30-May-07	MA-Corres	Resp to Re	Info	Postmarketing commitment issues.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

201254	UNITED STATES	1-Jun-07	MA-Corres	Resp to Re	Info	CMC information request letter dated 3-MAY-2007.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
201789	UNITED STATES	7-Jun-07	MA-Corres	Mtg/Teleco	Other	Requesting time change for teleconference scheduled 13-JUN-2007.	7-Jun-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
201791	UNITED STATES	7-Jun-07	MA-Corres	Mtg/Teleco	Other	Requested time changed granted to 2:30.	7-Jun-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
201902	UNITED STATES	8-Jun-07	MA-FDA C	Phone	Clinical Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
202438	UNITED STATES	14-Jun-07	MA-FDA C	Phone	Clinical Issues	Feedback on the completed Clinical Pharmacology Question.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
202516	UNITED STATES	18-Jun-07	MA-Corres	Mtg/Teleco	Minutes	22-MAY-2207.	18-Jun-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
203138	UNITED STATES	27-Jun-07	MA-Corres	Action Lett	Response	Response to approvable letter dated 22-JAN-2007.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
203138	UNITED STATES	27-Jun-07	MA-Corres	CMC Issues		Response to approvable letter dated 22-JAN-2007.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
203683	UNITED STATES	6-Jul-07	MA-Corres	Mtg/Teleco	Minutes	Minutes of 22-MAY-2007.	6-Jul-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

204455	UNITED STATES	16-Jul-07	MA-FDA C	Phone	CMC Issues	Follow-up regarding requests made during pre-operational visits.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
206120	UNITED STATES	30-Jul-07	MA-FDA C	Phone	CMC Issues	Response submission to CMC questions.	30-Jul-07	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
206579	UNITED STATES	7-Aug-07	MA-FDA C	Phone	CMC Issues	Pre-operational visit requested by FDA.	7-Aug-07	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
207799	UNITED STATES	23-Aug-07	MA (Pend)	CMC		Response to the approvable letter dated 23-JUL-2007.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
208221	UNITED STATES	29-Aug-07	MA-Corres	Resp to Re	Info	Complete response to approvable letter dated 22-JAN-2007.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
208738	UNITED STATES	5-Sep-07	MA-Corres	Resp to Re	Info	Due date will 29-FEB-2008.	5-Sep-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
208741	UNITED STATES	5-Sep-07	MA-FDA C	Phone	Other	Response to approvable letter being sent via FDA Gateway.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
213860	UNITED STATES	11-Oct-07	MA-Corres	Request	Info	Various issues.	11-Oct-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
213861	UNITED STATES	14-Oct-07	MA-Corres	Resp to Re	Info	Various issues.	14-Oct-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

213862	UNITED STATES	14-Oct-07	MA-Corres	General Corresp		14-Oct-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
213013	UNITED STATES	15-Oct-07	MA-Corres	General Corresp	Follow-up on the 29-AUG-2007.	15-Oct-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
213014	UNITED STATES	16-Oct-07	MA-Corres	Resp to Re Info		16-Oct-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
214267	UNITED STATES	16-Oct-07	MA-Corres	Action Lett Approval - Orig App	User fee goal date 29-FEB-2008.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
215711	UNITED STATES	15-Nov-07	MA-Corres	Request Info	Copy of the IR letter.	15-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
216018	UNITED STATES	20-Nov-07	MA-Corres	Request Info	Proprietary name feedback.	20-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
216019	UNITED STATES	20-Nov-07	MA-Corres	Resp to Re Info	Proprietary name feedback.	20-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
216020	UNITED STATES	20-Nov-07	MA-Corres	Request Info	Proprietary name feedback.	20-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
216335	UNITED STATES	20-Nov-07	MA-Corres	General Corresp	Proprietary name issues.	20-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

216835	UNITED STATES	27-Nov-07	MA-Corres	Mtg/Teleco	Req Response- Other		27-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
217021	UNITED STATES	29-Nov-07	MA-Corres	Request	Info	Proprietary name feedback request.	29-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
217310	UNITED STATES	30-Nov-07	MA-Corres	General	Corresp	Proprietary name issues.	30-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
217450	UNITED STATES	4-Dec-07	MA-Corres	Request	Info	Proprietary name feedback issues.	4-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219441	UNITED STATES	11-Dec-07	MA-Corres	Clinical Issu	Info-Request	Exposure data in patient-years for study 332 and 333.	11-Dec-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219442	UNITED STATES	11-Dec-07	MA-Corres	Resp to Re	Other		11-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219445	UNITED STATES	12-Dec-07	MA-Corres	Mtg/Teleco	Request for Meeting	To discuss study 302.	12-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219576	UNITED STATES	13-Dec-07	MA-Corres	Mtg/Teleco	Info	Meeting scheduled 17-JAN-2008.	13-Dec-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
218725	UNITED STATES	13-Dec-07	MA-Corres	Mtg/Teleco	Minutes	CMC - Pilot program minutes of the 29-NOV-2007 meeting.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

219578	UNITED STATES	14-Dec-07	MA-Corres	Mtg/Teleco Info	List of Wyeth's attendees for the 17-JAN-2008 meeting.	14-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219351	UNITED STATES	14-Dec-07	MA-Corres	Resp to Re Info		14-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
218739	UNITED STATES	14-Dec-07	MA-Corres	Clinical Issı Info Req-Response	Patient Exposure Year Data.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219585	UNITED STATES	17-Dec-07	MA-Corres	Clinical Issı Info-Request		17-Dec-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219628	UNITED STATES	17-Dec-07	MA-Corres	Clinical Issı Info-Request	Confirm that Analyses and Datasets will not be classified as a major amendment.	17-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219589	UNITED STATES	18-Dec-07	MA-Corres	General Corresp		18-Dec-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219590	UNITED STATES	18-Dec-07	MA-Corres	General Corresp		18-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219079	UNITED STATES	19-Dec-07	MA-Corres	CMC Issue Request-Response	Ammendment Response to CMC Information Request		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
219632	UNITED STATES	20-Dec-07	MA-Corres	Request Info	Proprietary name issues.	20-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

219339	UNITED STATES	20-Dec-07	MA-Corres	Clinical Iss	Info Req-Response	Information regarding studies 332 and 333.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
219633	UNITED STATES	21-Dec-07	MA-Corres	General Corresp			21-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220173	UNITED STATES	4-Jan-08	MA-Corres	General Corresp		Relapse Position Paper.	4-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220162	UNITED STATES	7-Jan-08	MA-Corres	Request	Info	Proposed Tradename.	7-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220378	UNITED STATES	8-Jan-08	MA-FDA C	Phone	CMC Issues	Status of the Agency review of 19-DEC-2007.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220744	UNITED STATES	11-Jan-08	MA-Corres	Resp to Re	Info	Proprietary information issues.	11-Jan-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220745	UNITED STATES	11-Jan-08	MA-Corres	Request	Info	Proprietary information issues.	11-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220759	UNITED STATES	11-Jan-08	MA-Corres	Resp to Re	Info	Proprietary information.	11-Jan-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
220760	UNITED STATES	11-Jan-08	MA-Corres	General Corresp			11-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

220903	UNITED STATES	14-Jan-08	MA (Pend)	Other		Relapse Prevention Position Paper.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
221052	UNITED STATES	15-Jan-08	MA-Corres	Mtg/Teleco	Info	List of attendees for the 17-JAN-2008 meeting.	15-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
221493	UNITED STATES	17-Jan-08	MA-Corres	Mtg/Teleco	Info	List of attendees. DMETS review found name acceptable.	17-Jan-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
221493	UNITED STATES	17-Jan-08	MA-Corres	Resp to Re	Info	List of attendees. DMETS review found name acceptable.	17-Jan-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
221494	UNITED STATES	17-Jan-08	MA-Corres	General Corresp		Tradename questions.	17-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
221555	UNITED STATES	17-Jan-08	MA-FDA C	Phone	Meeting Sched/Issues	Acceptability of the Randomized Withdrawl Study.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223096	UNITED STATES	25-Jan-08	MA-Corres	Request	Info	RiskMap plan.		Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
222607	UNITED STATES	25-Jan-08	MA-Corres	General Corresp		Copy of RiskMap letter.	25-Jan-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
222626	UNITED STATES	26-Jan-08	MA-Corres	General Corresp		Confirm receipt of letter - RiskMap.	26-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

222630	UNITED STATES	29-Jan-08	MA-Corres	General Corresp	Response to RiskMAP will probably be submitted this Friday or Monday.	29-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223123	UNITED STATES	1-Feb-08	MA-Corres	Mtg/Teleco Info	Questions for teleconference 4-FEB-2008.	1-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223097	UNITED STATES	3-Feb-08	MA-Corres	Mtg/Teleco Info	Dialing info for the teleconference on the 4-FEB-2008.	3-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223130	UNITED STATES	4-Feb-08	MA-Corres	Request Info		4-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223132	UNITED STATES	4-Feb-08	MA-Corres	Resp to Re Info		4-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
222864	UNITED STATES	4-Feb-08	MA (Pend)	Request-Response	Questions concerning RiskMAPs.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223266	UNITED STATES	5-Feb-08	MA-Corres	Labeling Other		5-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223268	UNITED STATES	7-Feb-08	MA-Corres	Mtg/Teleco Request - Other		7-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
223585	UNITED STATES	7-Feb-08	MA-Corres	Labeling Request			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

223585	UNITED STATES	7-Feb-08	MA-Corres	Phase IV C	Information-Request			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223665	UNITED STATES	8-Feb-08	MA-Corres	Request	Info	Various issues - Labeling and Phase 4 commitments.	8-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223666	UNITED STATES	8-Feb-08	MA-Corres	General Corresp			8-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223687	UNITED STATES	8-Feb-08	MA-Corres	Resp to Re	Info	Clarification response.	8-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223694	UNITED STATES	8-Feb-08	MA-Corres	Mtg/Teleco	Info	List of attendees 4-FEB-2008.	8-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223607	UNITED STATES	8-Feb-08	MA-Corres	Mtg/Teleco	Info	CMC pilot program of the unofficial minutes of 4-FEB-2008 meeting.	8-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223646	UNITED STATES	11-Feb-08	MA-Corres	Mtg/Teleco	Minutes	Pilot Program meeting minutes 4-FEB-2008.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223787	UNITED STATES	12-Feb-08	MA-Corres	Labeling	Revision - Request		12-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
223788	UNITED STATES	12-Feb-08	MA-Corres	General Corresp			12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

223790	UNITED STATES	12-Feb-08	MA-Corres	Phase IV C	Other		12-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223791	UNITED STATES	12-Feb-08	MA-Corres	Labeling	Issues	Update on the labeling revisions.	12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223826	UNITED STATES	12-Feb-08	MA-Corres	Labeling	Issues		12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223828	UNITED STATES	12-Feb-08	MA-Corres	Mtg/Teleco	Info	List of attendees for the 15-FEB-2008 teleconference.	12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223964	UNITED STATES	12-Feb-08	MA-FDA C	Phone	CMC Issues	Amendment to provide responses to FDA's 1-FEB-2008 e-mail.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223832	UNITED STATES	13-Feb-08	MA-Corres	Labeling	Request		13-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223833	UNITED STATES	13-Feb-08	MA-Corres	Labeling	Request-Response		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223978	UNITED STATES	13-Feb-08	MA-Corres	General	Corresp		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223979	UNITED STATES	13-Feb-08	MA-Corres	Mtg/Teleco	Info		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

223981	UNITED STATES	13-Feb-08	MA-Corres	Labeling	Other		13-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223967	UNITED STATES	13-Feb-08	MA-Corres	Labeling	Request-Response		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223974	UNITED STATES	13-Feb-08	MA-Corres	Labeling	Other	Additional information.	13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223961	UNITED STATES	14-Feb-08	MA-Corres	Clinical Issu	Other	Phase 4 Commitment comments.	14-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223965	UNITED STATES	14-Feb-08	MA-Corres	Request	Info		14-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
223966	UNITED STATES	14-Feb-08	MA-Corres	Resp to Re	Info		14-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224091	UNITED STATES	14-Feb-08	MA-Corres	Labeling	Rev Req - Response	E-mail dated 12-FEB-2008.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224131	UNITED STATES	15-Feb-08	MA-Corres	Mtg/Teleco	Request - Other	List of attendees for today's meeting.	15-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224400	UNITED STATES	15-Feb-08	MA-Corres	CMC Issues			15-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

224558	UNITED STATES	15-Feb-08	MA-FDA C	Phone	CMC Issues			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224112	UNITED STATES	15-Feb-08	MA (Pend)	CMC				FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224375	UNITED STATES	15-Feb-08	MA-Corres	Mtg/Teleco	Info	List of attendees for today's meeting.	15-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224374	UNITED STATES	15-Feb-08	MA-Corres	General	Corresp	Updated adverse events table.	15-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224373	UNITED STATES	15-Feb-08	MA-Corres	Labeling	Rev Req - Response		15-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224397	UNITED STATES	19-Feb-08	MA-Corres	Request	Info		19-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224398	UNITED STATES	19-Feb-08	MA-Corres	Phase IV C	Issues		19-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224399	UNITED STATES	19-Feb-08	MA-Corres	Phase IV C	Issues		19-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
224388	UNITED STATES	19-Feb-08	MA-Corres	Phase IV C	Issues	Change - Studies conducted in 8 weeks not 6.	19-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

224402	UNITED STATES	19-Feb-08	MA-Corres	Request	Info		19-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224557	UNITED STATES	19-Feb-08	MA-FDA C	Phone	CMC Issues	FDA's request to remove Impurities test from NDA.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224381	UNITED STATES	19-Feb-08	MA-Corres	Labeling	Other	Updated labeling.	19-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224383	UNITED STATES	19-Feb-08	MA-Corres	Labeling	Issues		19-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224384	UNITED STATES	19-Feb-08	MA-Corres	Phase IV C	Other		19-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224389	UNITED STATES	20-Feb-08	MA-Corres	Labeling	Issues		20-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224546	UNITED STATES	20-Feb-08	MA-Corres	Labeling	Request		20-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224548	UNITED STATES	20-Feb-08	MA-Corres	Labeling	Issues		20-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
224554	UNITED STATES	20-Feb-08	MA-Corres	Labeling	Request-Response		20-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

224533	UNITED STATES	20-Feb-08	MA-Corres	CMC Issues		Follow-up to telecon.	20-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224536	UNITED STATES	20-Feb-08	MA-Corres	CMC Issues		Summary of teleconference 19-FEB-2008.	20-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224544	UNITED STATES	20-Feb-08	MA-FDA C	Phone	Labeling	Doc dated 2007 in error.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224544	UNITED STATES	20-Feb-08	MA-FDA C	Phone	Other	Doc dated 2007 in error.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224568	UNITED STATES	20-Feb-08	MA-Corres	Labeling	Rev Req - Response		20-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224444	UNITED STATES	20-Feb-08	MA-Corres	Resp to Re	Info	CMC correspondence dated 15-FEB-2008.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224578	UNITED STATES	21-Feb-08	MA-Corres	Mtg/Teleco	Request for Meeting	Day of approval logistics.	21-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224579	UNITED STATES	21-Feb-08	MA-FDA C	Phone	CMC Issues	Remove impurities tests from NDA.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224583	UNITED STATES	21-Feb-08	MA-Corres	Labeling	Request		21-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

224585	UNITED STATES	21-Feb-08	MA-Corres	General Corresp	Discuss good communication practices.	21-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224531	UNITED STATES	21-Feb-08	MA-Corres	Labeling Draft			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224587	UNITED STATES	22-Feb-08	MA-Corres	Resp to Re Info		22-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224588	UNITED STATES	22-Feb-08	MA-Corres	Labeling Issues	Minor error in the last paragraph of section 10.	22-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224589	UNITED STATES	22-Feb-08	MA-Corres	General Corresp	Communication issues.	22-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224590	UNITED STATES	22-Feb-08	MA-Corres	Labeling Issues	Minor label correction fixed.	22-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224594	UNITED STATES	22-Feb-08	MA (Pend)	CMC			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224594	UNITED STATES	22-Feb-08	MA (Pend)	Request-Response			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
224991	UNITED STATES	26-Feb-08	MA-Corres	Labeling Issues		26-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

224992	UNITED STATES	27-Feb-08	MA-Corres	General Corresp	Tradename question.	27-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225165	UNITED STATES	27-Feb-08	MA-Corres	Labeling Issues		27-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225042	UNITED STATES	27-Feb-08	MA-Corres	Labeling Request	Updated labeling version.	27-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225177	UNITED STATES	28-Feb-08	MA-Corres	Phase IV C Issues		28-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225178	UNITED STATES	28-Feb-08	MA-Corres	Phase IV C Other		28-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225166	UNITED STATES	28-Feb-08	MA-FDA C	Phone Labeling			Wyeth	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225179	UNITED STATES	29-Feb-08	MA-Corres	General Corresp	Request copy of Approval letter ASAP.	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225180	UNITED STATES	29-Feb-08	MA-Corres	Labeling Issues		29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US
225219	UNITED STATES	29-Feb-08	MA-Corres	General Corresp	Thank you note.	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ US

225220	UNITED STATES	29-Feb-08		MA-Corres	General Corresp		Thank you note.	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
226310	UNITED STATES	29-Feb-08		MA-Corres	Action Lett	Approval - Orig App			Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225120	UNITED STATES	29-Feb-08		MA-Corres	Labeling	Draft			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225215	UNITED STATES	29-Feb-08		MA-Corres	Action Lett	Approval - Orig App		29-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225281	UNITED STATES	3-Mar-08	223002-01	MA-Promo	Routine	PPR			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
226311	UNITED STATES	3-Mar-08		MA-Corres	Promotiona	Information-Request	Advisory comments.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225321	UNITED STATES	3-Mar-08	215956-01	MA-Promo	Routine	WWW			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225322	UNITED STATES	3-Mar-08	216156-01	MA-Promo	Routine	WWW			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225323	UNITED STATES	3-Mar-08	223151-01	MA-Promo	Routine	WWW			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US

225324	UNITED STATES	3-Mar-08	224485-01	MA-Promo Routine	COT			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225325	UNITED STATES	3-Mar-08	224715-01	MA-Promo Routine	POT			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
225298	UNITED STATES	4-Mar-08		MA-Corres| Promotiona	Other	Initial launch campaign material sent to DDMAC.	4-Mar-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
226150	UNITED STATES	12-Mar-08		MA-Corres| Labeling	FPL			FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US
226281	UNITED STATES	13-Mar-08		MA-Corres| General Corresp		Provide a copy of the submission to the NDA in eCTD format.		FDA	Wyeth	NDA 21-992	DESVENLAFAXINE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S PRISTIQ	US